# EDGAR Filing Document

**Accession Number:** 0001990354
**File Stem:** 0001990354-25-000031
**Filing Date:** 2025-10
**Character Count:** 181805
**Document Hash:** a757ba117681489f246589189a646674
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001990354-25-000031.hdr.sgml**: 20251029

**ACCESSION NUMBER**: 0001990354-25-000031

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 102

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251029

**DATE AS OF CHANGE**: 20251029

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Waystar Holding Corp.
- **CENTRAL INDEX KEY:** 0001990354
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42125
- **FILM NUMBER:** 251429914

**BUSINESS ADDRESS:**
- **STREET 1:** 1550 DIGITAL DRIVE, #300
- **CITY:** LEHI
- **STATE:** UT
- **ZIP:** 84043
- **BUSINESS PHONE:** 844-492-9782

**MAIL ADDRESS:**
- **STREET 1:** 1550 DIGITAL DRIVE, #300
- **CITY:** LEHI
- **STATE:** UT
- **ZIP:** 84043

?xml version='1.0' encoding='ASCII'? way-20250930

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**(Mark One)**

⌧&nbsp;&nbsp;&nbsp;&nbsp;**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended September 30, 2025**

**OR**

☐&nbsp;&nbsp;&nbsp;&nbsp;**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from ______ to ______**

**Commission File Number 001-42125**

**Waystar Holding Corp.**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **84-2886542** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(I.R.S. Employer<br>Identification No.)** |
| **1550 Digital Drive, #300**<br>**Lehi, Utah 84043** | **84043** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(844) 492-9782**

Registrant's telephone number, including area code

**Not applicable**

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | **WAY** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ⌧ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ⌧ | Smaller reporting company | ☐ |
| | | Emerging growth company | ⌧ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ⌧

The registrant had outstanding 191,316,583 shares of common stock as of October 20, 2025.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Glossary**

The following definitions apply to these terms as used in this Quarterly Report on Form 10-Q:

"AI" means artificial intelligence;

"Bain" means those certain investment funds of Bain Capital, LP and its affiliates;

"CPPIB" means Canada Pension Plan Investment Board;

"Credit Facilities" means, collectively, the First Lien Credit Facility, the Revolving Credit Facility, and the Receivables Facility;

"Derby Topco" means Derby TopCo Partnership LP, our direct parent entity prior to the Equity Distribution, in which the Institutional Investors, other equity holders, and certain members of management previously held equity interests;

"EQT" means those certain investment funds of EQT AB and its affiliates;

"Equity Distribution" means the distribution of shares of common stock of the Company held by Derby TopCo to the limited partners of Derby TopCo in accordance with the limited partnership agreement of Derby Topco, which distribution occurred in connection with our initial public offering. Following the Equity Distribution, EQT, CPPIB, Bain, and other equity holders, including members of management, directly hold shares of common stock of the Company;

"Exchange Act" means the U.S. Securities Exchange Act of 1934, as amended;

"First Lien Credit Facility" means the term loan credit facility under the first lien credit agreement, dated as of October 22, 2019, by and among Waystar Technologies, Inc. and the lenders party thereto, as amended from time to time;

"GAAP" means U.S. generally accepted accounting principles;

"Institutional Investors" means EQT, CPPIB, and Bain, and their respective affiliates;

"JOBS Act" means the U.S. Jumpstart Our Business Startups Act of 2012, as amended;

"Net Revenue Retention Rate" means the total amount invoiced to clients in a given twelve-month period divided by the total amount invoiced to those same clients from the prior twelve-month period. See "Management's Discussion and Analysis of Financial Condition and Results of Operations—Key Performance Metrics and Non-GAAP Financial Measures—Net Revenue Retention Rate";

"2024 Form 10-K" means the 2024 Form 10-K filed with the SEC by Waystar Holding Corp. on February 18, 2025;

"Receivables Facility" means the receivables facility under the receivables financing agreement, dated as of August 13, 2021, by and among Waystar RC LLC, PNC Bank, National Association, as administrative agent, Waystar Technologies, Inc., as initial servicer, and PNC Capital Markets LLC, as structuring agent, as amended from time to time;

"Revolving Credit Facility" means the revolving credit facility under the first lien credit agreement, dated as of October 22, 2019, by and among Waystar Technologies, Inc. and the lenders party thereto, as amended from time to time;

"SEC" means the U.S. Securities and Exchange Commission;

"Second Lien Credit Facility" means the term loan credit facility under the second lien credit agreement, dated as of October 22, 2019, by and among Waystar Technologies, Inc. and the lenders party thereto, as amended from time to time;

"Securities Act" means the U.S. Securities Act of 1933, as amended;

"SOFR" means the Secured Overnight Financing Rate; and

"Waystar," the "Company," "we," "us," and "our" mean the business of Waystar Holding Corp. and its subsidiaries.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

Certain numerical figures have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them.

**Cautionary Statement Regarding Forward-Looking Statements**

This report contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-looking statements are included throughout this report and relate to matters such as our industry, business strategy, goals, and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity, and capital resources and other financial and operating information. We have used the words "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "seek," "foreseeable," the negative version of these words or similar terms and phrases to identify forward-looking statements in this report.

The forward-looking statements contained in this report are based on management's current expectations and are not guarantees of future performance. The forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our operation in a highly competitive industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to retain our existing clients and attract new clients;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to successfully execute on our business strategies in order to grow;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to accurately assess the risks related to acquisitions and successfully integrate acquired businesses, including the acquisition of Iodine Software Holdings, Inc. ("Iodine");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to establish and maintain strategic relationships;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the growth and success of our clients and overall healthcare transaction volumes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• consolidation in the healthcare industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our selling cycle of variable length to secure new client agreements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our implementation cycle that is dependent on our clients' timing and resources;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our dependence on our senior management team and certain key employees, and our ability to attract and retain highly skilled employees;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the accuracy of the estimates and assumptions we use to determine the size of our total addressable market;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to develop and market new solutions, or enhance our existing solutions, to respond to technological changes, or evolving industry standards;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the interoperability, connectivity, and integration of our solutions with our clients' and their vendors' networks and infrastructures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the performance and reliability of internet, mobile, and other infrastructure;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the consequences if we cannot obtain, process, use, disclose, or distribute the highly regulated data we require to provide our solutions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on certain third-party vendors and providers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any errors or malfunctions in our products and solutions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• failure by our clients to obtain proper permissions or provide us with accurate and appropriate information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the potential for embezzlement, identity theft, or other similar illegal behavior by our employees or vendors, and a failure of our employees or vendors to observe quality standards or adhere to environmental, social, and governance standards;

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our compliance with the applicable rules of the National Automated Clearing House Association and the applicable requirements of card networks;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• increases in card network fees and other changes to fee arrangements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the effect of payer and provider conduct which we cannot control;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• privacy concerns and security breaches or incidents relating to our platform;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the complex and evolving laws and regulations regarding privacy, data protection, and cybersecurity;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to adequately protect and enforce our intellectual property rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to use or license data and integrate third-party technologies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our use of "open source" software;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• legal proceedings initiated by third parties alleging that we are infringing or otherwise violating their intellectual property rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the heavily regulated industry in which we conduct business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the uncertain and evolving healthcare regulatory and political framework;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• health care laws and data privacy and security laws and regulations governing our Processing of personal information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reduced revenues in response to changes to the healthcare regulatory landscape;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• legal, regulatory, and other proceedings that could result in adverse outcomes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• consumer protection laws and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• contractual obligations requiring compliance with certain provisions of Bank Secrecy Act/anti-money laundering laws and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• existing laws that regulate our ability to engage in certain marketing activities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our full compliance with website accessibility standards;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any changes in our tax rates, the adoption of new tax legislation, or exposure to additional tax liabilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• limitations on our ability to use our net operating losses to offset future taxable income;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• losses due to asset impairment charges;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• restrictive covenants in the agreements governing our Credit Facilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• interest rate fluctuations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• unavailability of additional capital on acceptable terms or at all;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of general macroeconomic conditions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our history of net losses and our ability to achieve or maintain profitability;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the interests of the Institutional Investors may be different than the interests of other holders of our securities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our status as an "emerging growth company" and whether the reduced disclosure requirements applicable to "emerging growth companies" will make our common stock less attractive to investors; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the other factors described elsewhere in this report, including under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Quantitative and Qualitative Disclosures About Market Risk" and Part II, Item 1A, "Risk Factors" or as described under the heading "Risk factors" in our 2024 Form 10-K, or as described in the other documents and reports we file with the SEC.

These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this report. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

Any forward-looking statements made by us in this report speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. You should not place undue reliance on our forward-looking statements. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by any applicable securities laws.

Investors and others should note that we routinely announce financial and other material information using our Investor Relations website (investors.waystar.com), SEC filings, press releases, public conference calls and webcasts. We use these channels of distribution to communicate with our investors and members of the public about our company, our services and other items of interest. Information contained on our website is not part of this report or our other filings with the SEC.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Table of Contents**

---

| | |
|:---|:---|
| | **Page** |
| **<u>[Part I - Financial Information](#i17c1154a7f494eb98665b6e2e67bcada_13)</u>** | |
| &nbsp;&nbsp;&nbsp;<u>[Item 1. Financial Statements](#i17c1154a7f494eb98665b6e2e67bcada_16)</u> | [1](#i17c1154a7f494eb98665b6e2e67bcada_16) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Unaudited Condensed Consolidated Balance Sheets](#i17c1154a7f494eb98665b6e2e67bcada_19)</u> | [1](#i17c1154a7f494eb98665b6e2e67bcada_19) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Unaudited Condensed Consolidated Statements of Operations](#i17c1154a7f494eb98665b6e2e67bcada_22)</u> | [2](#i17c1154a7f494eb98665b6e2e67bcada_22) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss](#i17c1154a7f494eb98665b6e2e67bcada_25)</u>) | [3](#i17c1154a7f494eb98665b6e2e67bcada_25) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity](#i17c1154a7f494eb98665b6e2e67bcada_28)</u> | [4](#i17c1154a7f494eb98665b6e2e67bcada_28) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Unaudited Condensed Consolidated Statements of Cash Flows](#i17c1154a7f494eb98665b6e2e67bcada_31)</u> | [6](#i17c1154a7f494eb98665b6e2e67bcada_31) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Notes to Unaudited Condensed Consolidated Financial Statements](#i17c1154a7f494eb98665b6e2e67bcada_34)</u> | [7](#i17c1154a7f494eb98665b6e2e67bcada_34) |
| &nbsp;&nbsp;&nbsp;<u>[Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#i17c1154a7f494eb98665b6e2e67bcada_100)</u> | [26](#i17c1154a7f494eb98665b6e2e67bcada_100) |
| &nbsp;&nbsp;&nbsp;<u>[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#i17c1154a7f494eb98665b6e2e67bcada_139)</u> | [36](#i17c1154a7f494eb98665b6e2e67bcada_139) |
| &nbsp;&nbsp;&nbsp;<u>[Item 4. Controls and Procedures](#i17c1154a7f494eb98665b6e2e67bcada_142)</u> | [37](#i17c1154a7f494eb98665b6e2e67bcada_142) |
| **<u>[Part II - Other Information](#i17c1154a7f494eb98665b6e2e67bcada_145)</u>** |  |
| &nbsp;&nbsp;&nbsp;<u>[Item 1. Legal Proceedings](#i17c1154a7f494eb98665b6e2e67bcada_148)</u> | [38](#i17c1154a7f494eb98665b6e2e67bcada_148) |
| &nbsp;&nbsp;&nbsp;<u>[Item 1A. Risk Factors](#i17c1154a7f494eb98665b6e2e67bcada_151)</u> | [38](#i17c1154a7f494eb98665b6e2e67bcada_151) |
| &nbsp;&nbsp;&nbsp;<u>[Item 2. Unregistered Sales of Equity Securities](#i17c1154a7f494eb98665b6e2e67bcada_154)[and](#i17c1154a7f494eb98665b6e2e67bcada_154)[Use of Proceeds](#i17c1154a7f494eb98665b6e2e67bcada_154)</u> | [38](#i17c1154a7f494eb98665b6e2e67bcada_154) |
| &nbsp;&nbsp;&nbsp;<u>[Item 3. Defaults Upon Senior Securities](#i17c1154a7f494eb98665b6e2e67bcada_157)</u> | [38](#i17c1154a7f494eb98665b6e2e67bcada_157) |
| &nbsp;&nbsp;&nbsp;<u>[Item 4. Mine Safety Disclosures](#i17c1154a7f494eb98665b6e2e67bcada_160)</u> | [38](#i17c1154a7f494eb98665b6e2e67bcada_160) |
| &nbsp;&nbsp;&nbsp;<u>[Item 5. Other Information](#i17c1154a7f494eb98665b6e2e67bcada_163)</u> | [38](#i17c1154a7f494eb98665b6e2e67bcada_163) |
| &nbsp;&nbsp;&nbsp;<u>[Item 6. Exhibits](#i17c1154a7f494eb98665b6e2e67bcada_163)</u> | [38](#i17c1154a7f494eb98665b6e2e67bcada_163) |
| <u>[Signatures](#i17c1154a7f494eb98665b6e2e67bcada_172)</u> | [41](#i17c1154a7f494eb98665b6e2e67bcada_172) |

---

i

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Part I - Financial Information**

**Item 1. Financial Statements**

**Waystar Holding Corp.**

**Unaudited Condensed Consolidated Balance Sheets (in Thousands, Except for Share and Per Share Data)**

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| **Assets** | | |
| Current assets |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $421056 | $182133 |
| &nbsp;&nbsp;Restricted cash | 24301 | 22449 |
| &nbsp;&nbsp;Accounts receivable, net of allowance of $5,895 at September 30, 2025 and $5,885 at December 31, 2024 | 145675 | 145235 |
| &nbsp;&nbsp;Income tax receivable |  | 2838 |
| &nbsp;&nbsp;Prepaid expenses | 20557 | 14414 |
| &nbsp;&nbsp;Other current assets | 1993 | 3972 |
| &nbsp;&nbsp;&nbsp;Total current assets | 613582 | 371041 |
| &nbsp;&nbsp;Property, plant and equipment, net | 48172 | 46731 |
| &nbsp;&nbsp;Operating lease right-of-use assets, net | 11026 | 10820 |
| &nbsp;&nbsp;Intangible assets, net | 954967 | 1039049 |
| &nbsp;&nbsp;Goodwill | 3019999 | 3019999 |
| &nbsp;&nbsp;Deferred costs | 90131 | 82815 |
| &nbsp;&nbsp;Other long-term assets | 8479 | 6549 |
| &nbsp;&nbsp;&nbsp;Total assets | $4746356 | $4577004 |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;Accounts payable | $51401 | $47365 |
| &nbsp;&nbsp;Accrued compensation | 28300 | 31589 |
| &nbsp;&nbsp;Aggregated funds payable | 23848 | 22059 |
| &nbsp;&nbsp;Other accrued expenses | 26757 | 15930 |
| &nbsp;&nbsp;Deferred revenue | 9018 | 10527 |
| &nbsp;&nbsp;Current portion of long-term debt | 11099 | 11311 |
| &nbsp;&nbsp;Related party current portion of long-term debt | 569 | 357 |
| &nbsp;&nbsp;Current portion of operating lease liabilities | 5687 | 5591 |
| &nbsp;&nbsp;Current portion of finance lease liabilities | 973 | 904 |
| &nbsp;&nbsp;&nbsp;Total current liabilities | 157652 | 145633 |
| Long-term liabilities |  |  |
| &nbsp;&nbsp;Deferred tax liability | 123034 | 100523 |
| &nbsp;&nbsp;Long-term debt, net, less current portion | 1158411 | 1185411 |
| &nbsp;&nbsp;Related party long-term debt, net, less current portion | 55783 | 35211 |
| &nbsp;&nbsp;Operating lease liabilities, net of current portion | 11855 | 13133 |
| &nbsp;&nbsp;Finance lease liabilities, net of current portion | 10549 | 11290 |
| &nbsp;&nbsp;Deferred revenue - long-term | 5385 | 5739 |
| &nbsp;&nbsp;Other long-term liabilities | 1091 | 278 |
| &nbsp;&nbsp;&nbsp;Total liabilities | 1523760 | 1497218 |
| Commitments and contingencies (Note 19) |  |  |
| Stockholders' equity |  |  |
| &nbsp;&nbsp;Preferred stock $0.01 par value - 100,000,000 and 100,000,000 shares authorized as of September 30, 2025 and December 31, 2024, respectively; zero shares issued or outstanding as of September 30, 2025 and December 31, 2024, respectively |  |  |
| &nbsp;&nbsp;Common stock $0.01 par value - 2,500,000,000 and 2,500,000,000 shares authorized at September 30, 2025 and December 31, 2024, respectively; 174,667,840 and 172,108,240 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 1747 | 1722 |
| &nbsp;&nbsp;Additional paid-in capital | 3350190 | 3298083 |
| &nbsp;&nbsp;Accumulated other comprehensive income (loss) | (542) | 881 |
| &nbsp;&nbsp;Accumulated deficit | (128799) | (220900) |
| &nbsp;&nbsp;&nbsp;Total stockholders' equity | 3222596 | 3079786 |
| &nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $4746356 | $4577004 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Unaudited Condensed Consolidated Statements of Operations (in Thousands, Except for Share and Per Share Data)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Revenue | $268651 | $240112 | $795740 | $699447 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;Cost of revenue (exclusive of depreciation and amortization expenses) | 85136 | 80545 | 255525 | 236188 |
| &nbsp;&nbsp;Sales and marketing | 45158 | 38450 | 128805 | 117945 |
| &nbsp;&nbsp;General and administrative | 32422 | 22704 | 84914 | 88794 |
| &nbsp;&nbsp;Research and development | 12403 | 11082 | 36103 | 37303 |
| &nbsp;&nbsp;Depreciation and amortization | 33300 | 60185 | 100106 | 148635 |
| &nbsp;&nbsp;&nbsp;Total operating expenses | 208419 | 212966 | 605453 | 628865 |
| Income from operations | 60232 | 27146 | 190287 | 70582 |
| Other expense |  |  |  |  |
| &nbsp;&nbsp;Interest expense | (16613) | (17752) | (52195) | (122759) |
| &nbsp;&nbsp;Related party interest expense | (902) | (707) | (2475) | (3425) |
| Income/(loss) before income taxes | 42717 | 8687 | 135617 | (55602) |
| &nbsp;&nbsp;Income tax expense/(benefit) | 12069 | 3274 | 43516 | (17398) |
| Net income/(loss) | $30648 | $5413 | $92101 | $(38204) |
| Net income/(loss) per share: |  |  |  |  |
| &nbsp;&nbsp;Basic | $0.18 | $0.03 | $0.53 | $(0.27) |
| &nbsp;&nbsp;Diluted | $0.17 | $0.03 | $0.51 | $(0.27) |
| Weighted-average shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;Basic | 174352079 | 171578311 | 173388077 | 142367458 |
| &nbsp;&nbsp;Diluted | 181240033 | 176181511 | 181165738 | 142367458 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) (in Thousands)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income/(loss) | $30648 | $5413 | $92101 | $(38204) |
| Other comprehensive income (loss), before tax: |  |  |  |  |
| &nbsp;&nbsp;Interest rate swaps | (179) | (14440) | (1868) | (20624) |
| &nbsp;&nbsp;Available-for-sale securities | 32 |  |  |  |
| Income tax effect: |  |  |  |  |
| &nbsp;&nbsp;Interest rate swaps | 44 | 3506 | 445 | 5014 |
| &nbsp;&nbsp;Available-for-sale securities | (8) |  |  |  |
| Other comprehensive income/(loss), net of tax | (111) | (10934) | (1423) | (15610) |
| Comprehensive income/(loss), net of tax | $30537 | $(5521) | $90678 | $(53814) |

---

(1)Amounts reclassified out of accumulated other comprehensive income/(loss) into net interest expense included $2,171 and $8,788 for the three months ended September 30, 2025 and 2024, respectively, and included $4,060 and $26,085 for the nine months ended September 30, 2025 and 2024, respectively.

(2)The income tax effects of amounts reclassified out of accumulated other comprehensive income/(loss) were ($534) and ($2,134) for the three months ended September 30, 2025 and 2024, respectively, and $(999) and $(6,334) for the nine months ended September 30, 2025 and 2024, respectively.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (in Thousands, Except Share Data)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended September 30, 2025** | **Three months ended September 30, 2025** | **Three months ended September 30, 2025** | **Three months ended September 30, 2025** | **Three months ended September 30, 2025** | **Three months ended September 30, 2025** |
| | **Common Stock** | **Common Stock** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss)** | **Accumulated<br>Deficit** | **Total** |
| | **Shares** | **Amount** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss)** | **Accumulated<br>Deficit** | **Total** |
| **Balances at June 30, 2025** | 174146070 | $1741 | $3331277 | $(431) | $(159447) | $3173140 |
| Share-based compensation |  |  | 11525 |  |  | 11525 |
| Issuance of common stock under employee equity plans | 521770 | 6 | 7388 |  |  | 7394 |
| Net income |  |  |  |  | 30648 | 30648 |
| Other comprehensive income (loss) |  |  |  | (111) |  | (111) |
| **Balances at September 30, 2025** | 174667840 | $1747 | $3350190 | $(542) | $(128799) | $3222596 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended September 30, 2024** | **Three months ended September 30, 2024** | **Three months ended September 30, 2024** | **Three months ended September 30, 2024** | **Three months ended September 30, 2024** | **Three months ended September 30, 2024** |
| | **Common Stock** | **Common Stock** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss)** | **Accumulated<br>Deficit** | **Total** |
| | **Shares** | **Amount** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss)** | **Accumulated<br>Deficit** | **Total** |
| **Balances at June 30, 2024** | 166659634 | $1667 | $3178697 | $11126 | $(245392) | $2946098 |
| Stock-based compensation |  |  | 7949 |  |  | 7949 |
| Issuance of common stock under employee equity plans | 367485 | 4 | 1517 |  |  | 1521 |
| Issuance of common stock in initial public offering, net of issuance costs | 5059010 | 50 | 102650 |  |  | 102700 |
| Net loss |  |  |  |  | 5413 | 5413 |
| Other comprehensive income (loss) |  |  |  | (10934) |  | (10934) |
| **Balances at September 30, 2024** | 172086129 | 1721 | 3290813 | 192 | (239979) | 3052747 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (in Thousands, Except Share Data)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Nine months ended September 30, 2025** | **Nine months ended September 30, 2025** | **Nine months ended September 30, 2025** | **Nine months ended September 30, 2025** | **Nine months ended September 30, 2025** | **Nine months ended September 30, 2025** |
| | **Common Stock** | **Common Stock** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss)** | **Accumulated<br>Deficit** | **Total** |
| | **Shares** | **Amount** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss)** | **Accumulated<br>Deficit** | **Total** |
| **Balances at December 31, 2024** | 172108240 | $1722 | $3298083 | $881 | $(220900) | $3079786 |
| Share-based compensation |  |  | 29693 |  |  | 29693 |
| Issuance of common stock under employee equity plans | 2559600 | 25 | 22414 |  |  | 22439 |
| Net income |  |  |  |  | 92101 | 92101 |
| Other comprehensive income (loss) |  |  |  | (1423) |  | (1423) |
| **Balances at September 30, 2025** | 174667840 | 1747 | 3350190 | (542) | (128799) | 3222596 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Nine months ended September 30, 2024** | **Nine months ended September 30, 2024** | **Nine months ended September 30, 2024** | **Nine months ended September 30, 2024** | **Nine months ended September 30, 2024** | **Nine months ended September 30, 2024** |
| | **Common Stock** | **Common Stock** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss)** | **Accumulated<br>Deficit** | **Total** |
| | **Shares** | **Amount** | **Additional<br>Paid-In<br>Capital** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss)** | **Accumulated<br>Deficit** | **Total** |
| **Balances at December 31, 2023** | 121679902 | $1217 | $2234688 | $15802 | $(201775) | $2049932 |
| Stock-based compensation |  |  | 47867 |  |  | 47867 |
| Issuance of common stock under employee equity plans | 369905 | 5 | 1483 |  |  | 1488 |
| Repurchase of shares | (22688) | (1) | (843) |  |  | (844) |
| Capital distributions |  |  | (99) |  |  | (99) |
| Issuance of common stock in initial public offering, net of issuance costs | 50059010 | 500 | 1007717 |  |  | 1008217 |
| Net loss |  |  |  |  | (38204) | (38204) |
| Other comprehensive income (loss) |  |  |  | (15610) |  | (15610) |
| **Balances at September 30, 2024** | 172086129 | $1721 | $3290813 | $192 | $(239979) | $3052747 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Unaudited Condensed Consolidated Statements of Cash Flows (in Thousands)**

---

| | | |
|:---|:---|:---|
| | **Nine months ended September 30,** | **Nine months ended September 30,** |
| | **2025** | **2024** |
| **Cash flows from operating activities** |  |  |
| &nbsp;&nbsp;Net income/(loss) | $92101 | $(38204) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net income/(loss) to net cash provided by operating activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 100106 | 148635 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 29871 | 47400 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for bad debt expense | 2605 | 1642 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on extinguishment of debt | 711 | 20277 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | 22959 | (57984) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt discount and issuance costs | 2021 | 3301 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other |  | (99) |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (3045) | (13445) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax refundable | 2838 | 2227 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | (4980) | (1714) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred costs | (7116) | (14389) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term assets | (2362) | (515) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | 10580 | 9366 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | (1863) | (1256) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease right-of-use assets and lease liabilities | (1387) | (244) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 243039 | 104998 |
| **Cash flows from investing activities** |  |  |
| &nbsp;&nbsp;Purchase of property and equipment and capitalization of internally developed software costs | (17069) | (21044) |
| &nbsp;&nbsp;Purchase of investment securities | (206444) |  |
| &nbsp;&nbsp;Proceeds from sale of investment securities | 206444 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (17069) | (21044) |
| **Cash flows from financing activities** |  |  |
| &nbsp;&nbsp;Change in aggregated funds liability | 1789 | 7433 |
| &nbsp;&nbsp;Proceeds from equity offering, net of underwriting discounts |  | 1017074 |
| &nbsp;&nbsp;Payments of third-party IPO issuance costs |  | (3372) |
| &nbsp;&nbsp;Repurchase of shares |  | (844) |
| &nbsp;&nbsp;Proceeds from issuance of common stock from employee equity plans | 22439 | 1488 |
| &nbsp;&nbsp;Proceeds from issuances of debt, net of creditor fees |  | 545209 |
| &nbsp;&nbsp;Payments on debt | (8751) | (1550002) |
| &nbsp;&nbsp;Third-party fees paid in connection with issuance of new debt |  | (1410) |
| &nbsp;&nbsp;Finance lease liabilities paid | (672) | (611) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities | 14805 | 14965 |
| Increase in cash and cash equivalents during the period | 240775 | 98919 |
| Cash and cash equivalents and restricted cash–beginning of period | 204582 | 45428 |
| Cash and cash equivalents and restricted cash–end of period | $445357 | $144347 |
| **Supplemental disclosures of cash flow information** |  |  |
| &nbsp;&nbsp;Interest paid | $59303 | $101189 |
| &nbsp;&nbsp;Cash taxes paid (refunds received), net | 9439 | 38558 |
| **Non-cash investing and financing activities** |  |  |
| &nbsp;&nbsp;Fixed asset purchases in accounts payable | 539 | 586 |
| &nbsp;&nbsp;Unpaid third-party IPO issuance costs |  | 50 |
| **Reconciliation of Balance Sheet Cash Accounts to Cash Flow Statement** |  |  |
| &nbsp;&nbsp;&nbsp;Balance sheet |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | 421056 | 127125 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash | 24301 | 17222 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | 445357 | 144347 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

**1. Business**

Waystar Holding Corp. ("Waystar", "we", "us" or "our") is a provider of mission-critical cloud technology to healthcare organizations. Our enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. Our platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in better transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for our solutions extends throughout the United States and includes Puerto Rico and other U.S. Territories.

*Risks and Uncertainties—* We are subject to risks common to companies in similar industries, including, but not limited to, our operation in a highly competitive industry, our ability to retain our existing clients and attract new clients, our ability to establish and maintain strategic relationships, the growth and success of our clients and overall healthcare transaction volumes, consolidation in the healthcare industry, our selling cycle of variable length to secure new client agreements, our implementation cycle that is dependent on our clients' timing and resources, our ability to develop and market new solutions, or enhance our existing solutions, to respond to technological changes or evolving industry standards, the interoperability, connectivity, and integration of our solutions with our clients' and their vendors' networks and infrastructures, the performance and reliability of internet, mobile, and other infrastructure, the consequences if we cannot obtain, process, use, disclose, or distribute the highly regulated data we require to provide our solutions, impact of government regulations on our market, and our reliance on certain third-party vendors and providers.

On occasion, we enter into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent, or other intellectual property infringement claim by any third-party with respect to its technology. The terms of these indemnification agreements are generally perpetual any time after the execution of the agreement. The maximum potential future payments we could be required to make under these agreements is not determinable because it involves claims that may be made against us in the future but have not yet been made. Historically, we have not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.

We have entered into agreements with our directors or officers that may require us to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from their willful misconduct.

No liability associated with such indemnifications was recorded as of September 30, 2025 and December 31, 2024.

**2. Summary of Significant Accounting Policies**

**Basis of Financial Statement Presentation**

The financial statements include the consolidated balance sheets, statements of operations, statements of comprehensive income (loss), statements of changes in stockholders' equity, and statements of cash flows of Waystar and its subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP").

The accompanying unaudited consolidated financial statements and notes have been prepared in accordance with GAAP and applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the Company's financial position, results of operations, changes in stockholders' equity and cash flows. The results of operations for the nine months ended September 30, 2025 are not necessarily indicative of the results for the full year or the results for any future periods. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2024 in the 2024 Annual Report of Form 10-K filed with the SEC on February 18, 2025 (the "2024 Annual Report").

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

**Use of Estimates**

The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are used for, but are not limited to: (1) revenue recognition, including estimated expected customer life; (2) recoverability of accounts receivable and taxes receivable; (3) impairment assessment of goodwill and long-lived intangible assets; (4) fair value of intangibles acquired in business combinations; (5) litigation reserves; (6) depreciation and amortization; (7) fair value of stock options issued to employees and assumed as part of business combinations; (8) fair value of interest rate swaps; and (9) leases, including incremental borrowing rate. Future events and their effects cannot be predicted with certainty, and accordingly, accounting estimates require the exercise of judgment. We evaluate and update assumptions and estimates on an ongoing basis and may employ outside experts to assist in evaluations. Actual results could differ from the estimates used.

**Revenue Recognition**

We derive revenue primarily from providing access to our solutions for use in the healthcare industry and in doing so generate two types of revenue: (i) subscription revenue and (ii) volume-based revenue, which account for 99% of total revenue for all periods presented. We also derive revenue from implementation fees for our software, as well as hardware sales to facilitate patient payments.

We recognize revenue in accordance with ASC Topic 606, *Revenue from Contracts with Customers* ("ASC 606"), through the following five steps:

• identification of the contract, or contracts, with a client;

• identification of the performance obligations in the contract;

• determination of the transaction price;

• allocation of the transaction price to the performance obligations in the contract; and

• recognition of revenue when, or as, we satisfy a performance obligation

Our customers, referred to as clients elsewhere in this report, represent healthcare providers across all types of care settings, including physician practices, clinics, surgical centers, and laboratories, as well as large hospitals and health systems.

We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. The length of our contracts vary but are typically two to three years and generally renew automatically for successive one-year terms. Our revenue is reported net of applicable sales and use tax and is recognized as, or when, control of these services or products are transferred to clients, in an amount that reflects the consideration we expect to be entitled to in exchange for the contract's performance obligations.

Revenue from our subscription services as well as from our volume-based services represents a single promise to provide continuous access (i.e., a stand-ready obligation) to our software solutions in the form of a service. Our software products are made available to our clients via a cloud-based, hosted platform where our clients do not have the right or practical ability to take possession of the software. As each day of providing access to the software solutions is substantially the same and the client simultaneously receives and consumes the benefits as services are provided, these services are viewed as a single performance obligation composed of a series of distinct daily services.

Revenue from our subscription services is recognized over time on a ratable basis over the contract term beginning on the date that the service is made available to the client. Volume-based services are priced based on transaction, dollar volume or provider count in a given period. Given the nature of the promise is based on unknown quantities or outcomes of services to be performed over the contract term, the volume-based fee is determined to be variable consideration. The volume-based transaction fees are recognized each day using a time- elapsed output method based on the volume or transaction count at the time the clients' transactions are processed.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

Our other services are generally related to implementation activities across all solutions and hardware sales to facilitate patient payments. Implementation services are not considered performance obligations as they do not provide a distinct service to clients without the use of our software solutions. As such, implementation fees related to our solutions are billed upfront and recognized ratably over the customer's life. Implementation fees and hardware sales represent less than 1% of total revenue for all periods presented.

Our contracts with clients typically include various combinations of our software solutions. Determining whether such software solutions are considered distinct performance obligations that should be accounted for separately versus together requires significant judgment. Specifically, judgment is required to determine whether access to the Company's SaaS solutions is distinct from other services and solutions included in an arrangement.

We follow the requirements of ASC 606-10-55-36 through -40, Revenue from Contracts with Customers, Principal Agent Considerations, in determining the gross versus net revenue presentations for our performance obligations in the contract with a client. Revenue recorded where we act in the capacity of a principal is reported on a gross basis equal to the full amount of consideration to which we expect in exchange for the good or service transferred. Revenue recorded where we act in the capacity of an agent is reported on a net basis, exclusive of any consideration provided to the principal party in the transaction.

The principal versus agent evaluation is a matter of judgment that depends on the facts and circumstances of the arrangement and is dependent on whether we control the good or service before it is transferred to the client or whether we are acting as an agent of a third party. This evaluation is performed separately for each performance obligation identified. For the majority of our contracts, we are considered the principal in the transaction with the client and recognize revenue gross of any related channel partner fees or costs. We have certain agency arrangements where third parties control the goods or services provided to a client and we recognize revenue net of any fees owed to these third parties.

Payment terms and conditions vary by contract type, although our standard payment terms generally require payment within 30 to 60 days. In instances where the timing of revenue recognition differs from the timing of payment, we have determined our contracts do not generally include a significant financing component. The primary purpose of our invoicing terms is to provide clients with simplified and predictable ways of purchasing our products and services, not to receive financing from our clients or to provide clients with financing.

**Contract Costs**

*Incremental Costs of Obtaining a Contract*

Incremental costs of obtaining a contract primarily include commissions paid to our internal sales personnel. We consider all such commissions to be both incremental and recoverable since they are only paid when a contract is secured. These capitalized costs are amortized on a straight-line basis over the expected period of benefit, which is determined based on the average customer life, which includes anticipated renewals of contracts. As of September 30, 2025 and December 31, 2024, the total unamortized costs reported as deferred costs on our balance sheet amounted to $30.8 million and $29.0 million, respectively, for internal sales commissions. For the three months ended September 30, 2025 and 2024, amortization related to the sales commission asset was $3.3 million and $2.8 million, respectively. For the nine months ended September 30, 2025 and 2024, amortization related to the sales commission asset was $9.6 million and $7.8 million, respectively. The aforementioned amortization amounts are included in sales and marketing in our consolidated statements of operations.

*Costs to Fulfill a Contract*

We capitalize costs incurred to fulfill contracts that i) relate directly to the contract, ii) are expected to generate resources that will be used to satisfy performance obligations under the contract, and iii) are expected to be recovered through revenue generated under the contract. Costs incurred to implement clients on our solutions (e.g., direct labor) are capitalized and amortized on a straight-line basis over the estimated customer life if we expect to recover those costs. As of September 30, 2025 and December 31, 2024, the total unamortized costs reported as deferred costs on our balance sheet amounted to $59.3 million and $53.8 million, respectively, for fulfillment costs. For the three months ended September 30, 2025 and 2024, amortization related to the fulfillment cost asset was $4.2 million and $3.2 million, respectively. For the nine months ended September 30, 2025 and 2024, amortization related to the fulfillment cost asset was $11.8 million and

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

$8.9 million, respectively. The aforementioned amortization amounts are included in the costs of revenue in our consolidated statements of operations.

There were no impairment losses relating to deferred costs during the periods presented.

**Channel Partners**

We account for fees paid to channel partners within sales and marketing expenses in the accompanying statements of operations. For the three months ended September 30, 2025 and 2024, we recorded fees to all channel partners of $19.8 million and $17.0 million, respectively. For the nine months ended September 30, 2025 and 2024, we recorded fees to all channel partners of $57.1 million and $47.6 million, respectively. As we are primarily responsible for contracting with and fulfilling contracts for the end user, we record revenue gross of related channel partner fees.

**Cash and cash equivalents**

We consider highly liquid investments with an original maturity of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts, which, at times, may exceed federally insured limits. We have not experienced any credit losses in such accounts.

**Investment securities**

Our short-term investments, which consist of debt securities, are stated at fair value. These debt securities have been categorized as available-for-sale and classified as current assets given their maturity date is twelve months or less. Unrealized holding gains and losses for debt securities, net of applicable deferred taxes, are included in other comprehensive income or loss as a component of stockholders' equity until realized from a sale or an expected credit loss is recognized. For the purpose of determining realized gross gains and losses for debt securities sold, that are included as a component of interest income/(expense) in the consolidated statements of income, the cost of investment securities sold is based upon specific identification. We recorded $1.4 million and $2.0 million of interest income on investment securities for the three and nine months ended September 30, 2025, within "Other expense" of our statements of operations. For the period ended September 30, 2025 we had purchases of short-term investments of $206.4 million that were liquidated in the same period to help fund the acquisition of Iodine Software Holdings, Inc. ("Iodine"). No material gain or loss was recognized in the sale of these short-term investments.

Under the current expected credit losses model expected losses on available for sale debt securities are recognized through an allowance for credit losses rather than as reductions in the amortized cost of securities. For debt securities whose fair value is less than their amortized cost which we do not intend to sell or are not required to sell, we evaluate the expected cash flows to be received as compared to amortized cost and determine if an expected credit loss has occurred. In the event of any expected credit loss, only the amount of impairment associated with the expected credit loss is recognized in income with the remainder, if any, of the loss recognized in other comprehensive income. To the extent we have the intent to sell the debt security, or it is more likely than not we will be required to sell the debt security before recovery of our amortized cost basis, we recognize an impairment loss in income in an amount equal to the full difference between the amortized cost basis and the fair value.

There were no impairment losses relating to our investment securities during the periods presented.

**Recently Issued Accounting Pronouncements Not Yet Adopted**

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09, "Improvements to Income Tax Disclosures", which requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. For public business entities, the ASU will be effective for annual periods beginning after December 15, 2024. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. We are

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

currently evaluating the effect of the adoption of this amendment on our consolidated and condensed consolidated financial statements.

In November 2024, the FASB issued ASU 2024-13, "Expense Disaggregation Disclosures." The standard is intended to benefit investors by providing more detailed information about expenses that is critically important in understanding an entity's performance, assessing an entity's prospects for future cash flows, and comparing an entity's performance over time and with that of other entities. For public business entities, this ASU will be effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The amendments in this Update should be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this Update or (2) retrospectively to any or all prior periods presented in the financial statements. We are currently evaluating the effect of the adoption of this amendment on our consolidated financial statements.

In September 2025, the FASB issued ASU 2025-06, "Targeted Improvements to the Accounting for Internal-Use Software" to modernize the accounting guidance for the costs to develop software for internal use. The new guidance amends the existing standard that refers to various stages of a software development project to align better with current software development methods, such as agile programming. The new guidance will be effective for all entities for annual periods beginning after December 15, 2027. The guidance can be applied on a fully prospective basis, a modified basis for in-process projects, or a full retrospective basis. We are currently evaluating the effect of the adoption of this amendment on our consolidated financial statements.

**3. Revenue Recognition**

***Disaggregation of Revenue***

The following table presents revenues disaggregated by revenue type and the timing of revenue recognition (in thousands):

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
| |<br>**Recognition** | **2025** | **2024** | **2025** | **2024** |
| Subscription revenue | Over time | $134450 | $117993 | $390599 | $336421 |
| Volume-based revenue | Over time | 132342 | 120678 | 400551 | 358723 |
| Implementation services and other revenue | Various | 1859 | 1441 | 4590 | 4303 |
| Total revenues |  | $268651 | $240112 | $795740 | $699447 |

---

***Contract Liabilities***

We derive our revenue from contracts with clients primarily through subscription fees and volume-based fees. Our payment terms with the client generally comprise an initial payment for implementation services, which includes client enrollment and the setup of contracted solutions on our platform. These implementation fees are due upon contract execution. Additionally, subscription fees are earned on an ongoing basis, which are invoiced monthly.

Client payments received in advance of fulfilling the corresponding performance obligations are recorded as contract liabilities. Implementation fees are recognized over the customer life, with any unrecognized amounts deferred as contract liabilities. These amounts are reported as deferred revenue on our consolidated balance sheet.

Revenue recognized from amounts included in deferred revenue as of the beginning of the period was $0.8 million and $0.7 million for the three months ended September 30, 2025 and 2024, respectively. Revenue recognized from the amounts included in deferred revenue as of the beginning of the period was $9.1 million and $10.2 million for the nine months ended September 30, 2025 and 2024, respectively.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

***Transaction Price Allocated to Remaining Performance Obligations***

At September 30, 2025, the transaction price related to unsatisfied performance obligations that are expected to be recognized for the next 12 months and greater than 12 months was $60.4 million and $15.0 million, respectively.

The transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts does not include revenue related to performance obligations that are part of a contract with an original expected duration of one year or less.

Additionally, the balance does not include variable consideration that is allocated entirely to wholly unsatisfied promises that form part of a single performance obligation composed of a series of distinct daily services.

Remaining performance obligation estimates are subject to change and are affected by several factors, including terminations and changes in the timing and scope of contracts, arising from contract modifications.

**4. Segments**

Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. We have one business activity and there are no segment managers who are held accountable for operations, operating results and plans for products or components below the consolidated unit level. The geographical location of our customers has no impact on strategy or products offered. The "chief operating decision maker," or CODM, assesses performance and allocates resources using a consolidated profitability metric as discussed below. Accordingly, we have determined that we operate in a single reportable operating segment.

Our CODM is our Chief Executive Officer. On a monthly basis, our CODM reviews the following financial information presented on a consolidated basis. The key profitability metric used for purposes of making key personnel staffing decisions, approving operating budgets and forecasts, and making strategy decisions is Net Income as detailed below. See Note 3 for our disaggregated revenue by type.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
| *($in thousands)* | **2025** | **2024** | **2025** | **2024** |
| **Total Revenue** | $268651 | $240112 | $795740 | $699447 |
| &nbsp;&nbsp;Less: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Materials & connectivity | 60061 | 57877 | 182784 | 168875 |
| &nbsp;&nbsp;&nbsp;Labor & associated expenses | 25075 | 22668 | 72740 | 67313 |
| &nbsp;&nbsp;&nbsp;Research & development | 12403 | 11082 | 36103 | 37303 |
| &nbsp;&nbsp;&nbsp;Sales & marketing | 45158 | 38450 | 128805 | 117945 |
| &nbsp;&nbsp;&nbsp;General and administrative | 32422 | 22704 | 84914 | 88794 |
| &nbsp;&nbsp;&nbsp;Depreciation | 5449 | 21105 | 16024 | 31395 |
| &nbsp;&nbsp;&nbsp;Amortization | 27851 | 39080 | 84082 | 117240 |
| &nbsp;&nbsp;&nbsp;Interest and non-operating expenses, net | 17515 | 18459 | 54672 | 126184 |
| &nbsp;&nbsp;&nbsp;Income tax expense (benefit) | 12069 | 3274 | 43515 | (17398) |
| **Segment Net income/(loss)** | $30648 | $5413 | $92101 | $(38204) |
| **Consolidated Net income/(loss)** | $30648 | $5413 | $92101 | $(38204) |

---

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

**5. Fair Value Measurements and Disclosures**

The following table presents the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis (in thousands):

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Balance Sheet Classification** | **Carrying Value** | **Level 1** | **Level 2** | **Level 3** |
| **September 30, 2025** | | | | | |
| Other financial assets: |  |  |  |  |  |
| &nbsp;&nbsp;Interest rate swaps | Other current assets | $315 | $— | $315 | $— |
| Other financial liabilities: |  |  |  |  |  |
| &nbsp;&nbsp;Interest rate swaps | Other accrued expenses | $217 | $— | $217 | $— |
| &nbsp;&nbsp;Interest rate swaps | Other long-term liabilities | $815 | $— | $815 | $— |
| **December 31, 2024** |  |  |  |  |  |
| Other financial assets: |  |  |  |  |  |
| &nbsp;&nbsp;Interest rate swaps | Other current assets | $1127 | $— | $1127 | $— |
| &nbsp;&nbsp;Interest rate swaps | Other long-term assets | $22 | $— | $22 | $— |

---

The fair values of our interest rate swaps are based on the sum of all future net present value cash flows. The future cash flows are derived based on the terms of our interest rate swaps, as well as considering published discount factors, and projected SOFR curve. The fair value of long-term debt was determined using the present value of future cash flows based on the borrowing rates currently available for debt with similar terms and maturities. The carrying value of our first lien term loan facility was $1,154.8 million and $1,163.5 million compared to a fair value of $1,151.9 million and $1,169.4 million at September 30, 2025 and December 31, 2024, respectively. There were no transfers in or out of Level 3 during the periods presented.

As of September 30, 2025 and December 31, 2024, the carrying value of cash equivalents, accounts receivable, accounts payable, accrued liabilities, and other current assets and liabilities approximates fair value due to the short maturities of these instruments. Interest rate swaps are Level 2 instruments whose fair value is derived from discounted cash flows adjusted for nonperformance risk. Investment securities are Level 2 instruments whose fair value is observed through market data of similar securities. Money market funds are Level 1 instruments whose fair value is observed through daily quoted prices of similar assets. Money market funds are considered cash equivalents because they have a maturity of less than three months and are highly liquid.

**6. Property and Equipment, Net**

The balances of the major classes of property and equipment are as follows (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| Computer hardware | $42799 | $39833 |
| Capitalized internal-use software | 50402 | 40281 |
| Purchased computer software | 22938 | 22789 |
| Furniture and fixtures | 4010 | 3642 |
| Office equipment | 266 | 247 |
| Leasehold improvements | 4236 | 3778 |
| Internal-use software in progress | 18745 | 15361 |
|  | 143396 | 125931 |
| &nbsp;&nbsp;Accumulated depreciation | (95224) | (79200) |
| Total | $48172 | $46731 |

---

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

Depreciation of fixed assets, including the amortization of capitalized software, for the three months ended September 30, 2025 and 2024 was $5.4 million and $21.1 million, respectively. Depreciation of fixed assets, including the amortization of capitalized software, for the nine months ended September 30, 2025 and 2024 was $16.0 million and $31.4 million, respectively.

We capitalized $4.6 million and $13.5 million in software development costs for the three and nine months ended September 30, 2025, respectively. We capitalized $4.3 million and $12.1 million in software developments costs for the three and nine months ended September 30, 2024, respectively. Amortization of capitalized software was $3.6 million and $2.7 million for the three months ended September 30, 2025 and 2024, respectively, and was $10.3 million and $7.4 million for the nine months ended September 30, 2025 and 2024, respectively. The net book value of capitalized software development costs was $32.8 million and $29.6 million as of September 30, 2025 and December 31, 2024, respectively.

There were no impairments of property and equipment for the three and nine months ended September 30, 2025 and 2024, respectively.

**7. Goodwill and Other Intangible Assets**

Goodwill has a balance of $3,020.0 million as of both September 30, 2025 and December 31, 2024. There were no additions, disposals or impairments to goodwill during the three and nine months ended September 30, 2025 and 2024.

Amortization for definite-lived intangible assets is as follows (in thousands, except useful life):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Gross Carrying <br>Amount** | **Accumulated<br>Amortization** | **Net<br>Carrying<br>Value** | **Weighted-<br>Average<br>Remaining<br>Useful Life** |
| **As of September 30, 2025** | | | | |
| Customer relationships | $1429400 | $(511890) | $917510 | 10.4 |
| Purchased developed technology | 44100 | (22837) | 21263 | 4.3 |
| Tradenames and trademarks | 40300 | (24106) | 16194 | 4.1 |
| Total | $1513800 | $(558833) | $954967 |  |
| **As of December 31, 2024** |  |  |  |  |
| Customer relationships | $1429400 | $(440729) | $988671 | 11.1 |
| Purchased developed technology | 81800 | (50875) | 30925 | 4.2 |
| Tradenames and trademarks | 40700 | (21247) | 19453 | 4.7 |
| Total | $1551900 | $(512851) | $1039049 |  |

---

Amortization expense was $27.9 million and $39.1 million for the three months ended September 30, 2025 and 2024, respectively and was $84.1 million and $117.2 million for the nine months ended September 30, 2025 and 2024, respectively. During the three and nine months ended September 30, 2025, gross carrying amount of definite-lived intangible assets decreased by $38.1 million due to disposals of fully amortized assets.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

**8. Leases**

The following table presents components of lease expense for the three and nine months ended September 30, 2025 and 2024, respectively (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Finance lease cost |  |  |  |  |
| &nbsp;&nbsp;Amortization of right-of-use assets | $— | $13442 | $— | $14236 |
| &nbsp;&nbsp;Interest on lease liabilities | 173 | 186 | 530 | 568 |
| Operating lease cost | 1194 | 1978 | 3465 | 3752 |
| Variable lease cost | 149 | 206 | 527 | 357 |
| Short-term lease | 227 | 162 | 620 | 526 |
| Total lease cost | $1743 | $15974 | $5142 | $19439 |

---

Maturities of lease liabilities as of September 30, 2025 are as follows (in thousands):

---

| | | |
|:---|:---|:---|
| | **Operating Leases** | **Finance Leases** |
| 2025 | $1722 | $401 |
| 2026 | 6198 | 1641 |
| 2027 | 3924 | 1678 |
| 2028 | 3624 | 1714 |
| 2029 | 2182 | 1752 |
| Thereafter | 1689 | 7557 |
| Total future minimum lease payments | 19339 | 14743 |
| Less: Interest | 1797 | 3221 |
| Total | $17542 | $11522 |

---

Supplemental cash flow information related to leases for the three and nine months ended September 30, 2025 and 2024 are as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Cash paid for amounts included in the measurement of lease liabilities: |  |  |  |  |
| &nbsp;&nbsp;Operating cash flows for operating leases | $1622 | $1358 | $4852 | $3995 |
| &nbsp;&nbsp;Financing cash flows for financing leases | 401 | 394 | 1095 | 1179 |
| Right-of-use assets obtained in exchange for new lease liabilities: |  |  |  |  |
| &nbsp;&nbsp;Operating leases | $— | $2411 | $— | $3005 |

---

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

Supplemental balance sheet information related to leases as of September 30, 2025 and December 31, 2024 are as follows:

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| Weighted average remaining lease term (years): |  |  |
| &nbsp;&nbsp;Operating leases | 3.8 | 4.1 |
| &nbsp;&nbsp;Financing leases | 8.3 | 9.1 |
| Weighted average discount rate: |  |  |
| &nbsp;&nbsp;Operating leases | 4.9 | 4.7 |
| &nbsp;&nbsp;Financing leases | 5.9 | 5.9 |

---

**9. Income Taxes**

We recognized income tax expense of $12.1 million and income tax benefit of $3.3 million for the three months ended September 30, 2025 and 2024, respectively, based on the quarter-to-date pre-tax income. We recognized income tax expense of $43.5 million and income tax benefit of $17.4 million for the nine months ended September 30, 2025 and 2024, respectively, based on the year-to-date pre-tax income. The Company's effective income tax rate was 28.3% and 37.7% for the three months ended September 30, 2025 and 2024, respectively. The Company's effective income tax rate was 32.1% and 31.3% for the nine months ended September 30, 2025 and 2024, respectively. Differences in the effective tax rate and statutory federal income tax rate of 21% are primarily driven by the impact of certain limitations on the deductibility of stock-based compensation recognized for financial reporting purposes as well as state income taxes and research and development credits claimed.

On July 4, 2025, H.R.1, the budget reconciliation bill known as the "One Big Beautiful Bill Act", was signed into law in the U.S. This legislation includes significant changes to U.S. tax law impacting corporate tax rates, bonus depreciation, interest limitations under Internal Revenue Code Section 163(j), and the treatment of domestic research and development expenditures. Following the enactment of the OBBBA, the Company recognized the tax effects of the legislation in the interim period that included the enactment date, as required under ASC 740. The Company has evaluated the impact of the OBBBA on deferred tax assets and liabilities, including adjustments to valuation allowances, and has reflected these effects in the consolidated financial statements for the three and nine months ended September 30, 2025. The impacts of adopting the tax law change did not materially impact the net income tax expense or deferred tax balances.

**10. Accounts Receivable Securitization**

As of September 30, 2025 and December 31, 2024, we had $80.0 million and $80.0 million, respectively, outstanding under a receivables financing agreement with a counterparty as the lender, which provides for a three-year receivables facility with a limit of $80.0 million (the "Receivables Facility"). Pursuant to the Receivables Facility, we sell and/or contribute current and future receivables to Waystar RC, LLC as the Special Purpose Entity ("SPE"). The SPE, in turn, pledges its interests in the receivables to the counterparty, which either makes loans or issues letters of credit on behalf of the SPE. All receivables remain on our balance sheet as they continue to be the property of our consolidated entities under the securitization.

The interest rate under the Receivables Facility is 1.61% per annum above the SOFR rate with a minimum base of 0%. The SOFR is adjusted each thirty-day period to the thirty-day SOFR rate. Interest under the Receivables Facility is paid monthly in arrears. At September 30, 2025, the effective interest rate for the Receivables Facility is 5.74%.

All principal under the Receivables Facility is due on October 31, 2026.

The Receivables Facility contains certain covenants which, among other things, require we maintain certain collection thresholds with respect to our accounts receivable. We were in compliance with all such debt covenants during the periods presented.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

**11. Debt**

Debt instruments consist primarily of term notes, revolving lines of credit, and a Receivables Facility as follows (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 30,** | **December 31,** |
| | **2025** | **2024** |
| First lien term loan facility outstanding debt | $1154795 | $1163545 |
| Revolving credit facility |  |  |
| Receivables facility outstanding debt | 80000 | 80000 |
| Total outstanding debt | 1234795 | 1243545 |
| Unamortized debt issuance costs | (8933) | (11255) |
| Current portion of long-term debt | (11668) | (11668) |
| Total long-term debt, net | $1214194 | $1220622 |

---

The maturity of long-term principal payments (excluding debt discount) at September 30, 2025 is as follows (in thousands):

---

| | |
|:---|:---|
| 2025 | $2918 |
| 2026 | 91668 |
| 2027 | 11668 |
| 2028 | 11668 |
| 2029 | 1116873 |
|  | $1234795 |

---

As of September 30, 2025 and December 31, 2024, there is no outstanding balance on our revolving credit facility. The interest rate under the revolving credit facility is 1.75% per annum above the SOFR rate with a minimum base of 0.00%. The SOFR is adjusted each thirty-day period to the thirty-day SOFR rate. At September 30, 2025, the effective interest rate for the revolving credit facility is 5.88%.

On August 12, 2025, we executed the eleventh amendment on the First Lien Credit Agreement whereby the outstanding balance was repriced being an interest rate of 2.00% per annum above the SOFR rate with a minimum base of 0.00% ("August 2025 First Lien Repricing"). There was no change in the outstanding loan balance before repricing and after repricing and the maturity date was not impacted by the amendment. As part of the August 2025 First Lien Repricing, we recorded $0.7 million in third-party fees that were expensed immediately, which were recorded in general and administrative expenses in our consolidated statements of operations. We recorded a loss on extinguishment of $0.7 million for the three and nine months ended September 30, 2025 related to the August 2025 First Lien Repricing. The SOFR is adjusted each thirty-day period to the thirty-day SOFR rate. Interest under the First Lien Credit Facility is paid monthly in arrears. At September 30, 2025, the effective interest rate for First Lien Credit Facility is 6.34%.

Principal on the First Lien Credit Facility is payable in 20 equal quarterly installments with the remaining balance to be paid on October 22, 2029. As of September 30, 2025, there are 16 payments remaining. The First Lien Credit Agreement contains certain covenants which, among other things, restrict our ability to incur additional indebtedness. We were in compliance with such debt covenants as of September 30, 2025.

We had unamortized debt issuance costs of $8.9 million and $11.3 million as of September 30, 2025 and December 31, 2024, respectively.

In connection with the Revolving Credit Facility, unamortized debt issuance costs were $1.6 million and $2.1 million as of September 30, 2025 and December 31, 2024, respectively.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

**12. Derivative Financial Instruments**

To mitigate the risk of a rise in interest rates on the First Lien Credit Facility, we entered into interest rate swaps on January 13, 2023, April 1, 2025 and April 9, 2025. We attempt to minimize our interest risk exposure by fixing our rate through the utilization of interest rate swaps, which are derivative instruments. The interest rate swaps mitigate the exposure on the variable component of interest on our First Lien Credit Facility. The interest rate swaps result in the fixed interest rate shown in the table below on the swapped portion of the First Lien Credit Facility. Our swaps are entered into with financial institutions that participate in the First Lien Credit Facility. By using a derivative instrument to hedge exposures to changes in interest rates, we expose ourselves to credit risk due to the possible failure of the counterparty to perform under the terms of the derivative contract.

As of September 30, 2025 and December 31, 2024, we have the following interest rate swap agreements designated as a hedging instruments:

---

| | | | |
|:---|:---|:---|:---|
| **Effective Dates** | **Floating Rate Debt** | **Floating Rate Debt** | **Fixed Rates** |
| January 31, 2023 through January 31, 2026 | $506.7 | million | 3.87% |
| April 1, 2025 through January 30, 2026 | 80.0 | million | 3.59% |
| January 31, 2026 through March 31, 2027 | 275.0 | million | 3.59% |
| January 31, 2026 through March 31, 2027 | 275.0 | million | 3.27% |

---

The gain or loss on the swaps is recognized in accumulated other comprehensive income/(loss) and reclassified into earnings as adjustments to interest expense in the same period or periods during which the swaps affect earnings. Gains or losses on the swaps representing hedge components excluded from the assessment of effectiveness are recognized in current earnings.

The effect of derivative instruments designated as hedging instruments on the accompanying consolidated financial statements is as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Derivatives - Cash Flow Hedging Relationships** | **Amount of Gain or<br>(Loss) Recognized<br>in AOCI/AOCL on<br>Derivative** | **Location of Gain or<br>(Loss) Reclassified<br>from AOCI/AOCL<br>into Income** | **Amount of Gain or<br>(Loss) Reclassified<br>from AOCI/AOCL<br>into Income** | **Total Interest<br>Expense on<br>Consolidated<br>Statements of<br>Operations** |
| Interest rate swaps: |  |  |  |  |
| &nbsp;&nbsp;Three months Ended September 30, 2025 | $(135) | Interest expense | $736 | $(17515) |
| &nbsp;&nbsp;Three months Ended September 30, 2024 | $(10934) | Interest expense | $8788 | $(18459) |
| &nbsp;&nbsp;Nine Months Ended September 30, 2025 | $(1423) | Interest expense | $2026 | $(54670) |
| &nbsp;&nbsp;Nine Months Ended September 30, 2024 | $(15610) | Interest expense | $26085 | $(126184) |

---

The net amount of accumulated other comprehensive income expected to be reclassified to interest income in the next twelve months is $0.1 million.

**13. Related Party Transactions**

At September 30, 2025 and December 31, 2024, we had $56.4 million and $35.6 million, respectively, of outstanding debt as part of the First Lien Credit Facility from Bain Affiliated Funds and CPPIB Credit Investments III Inc., affiliates of Bain Capital LP and Canada Pension Plan Investment Board ("Affiliated Debtholders"). Interest expense associated with and

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

paid to Affiliated Debtholders was $0.9 million and $0.7 million for the three months ended September 30, 2025 and 2024, respectively and $2.5 million and $3.4 million for the nine months ended September 30, 2025 and 2024, respectively.

CPPIB has an ownership interest in us and a significant interest in the landlord that leases us office space under an operating lease agreement in Houston, Texas. For the three months ended September 30, 2025 and 2024, we expensed zero and $0.1 million, respectively, and for the nine months ended September 30, 2025 and 2024, we expensed zero and $0.2 million, respectively, for this office space lease in general and administrative expense.

Bain Capital LP has an ownership interest in us and a significant interest in some clients for whom we provide software solutions. For the three months ended September 30, 2025 and 2024, we earned revenue of $0.8 million from five clients and $0.4 million from four clients, respectively. For the nine months ended September 30, 2025 and 2024, we earned revenue of $1.9 million from five clients and $1.2 million from four clients, respectively. They also have an ownership interest in us and a significant interest in two vendors that provide us with software solutions. For the three months ended September 30, 2025 and 2024, we expensed $0.6 million and $0.1 million, respectively, and for the nine months ended September 30, 2025 and 2024, we expensed $1.8 million and $0.3 million for software services from these vendors in cost of revenue expense.

**14. Common and Preferred Stock**

In connection with our initial public offering ("IPO"), the Company's amended and restated certificate of incorporation became effective on June 10, 2024, which authorizes the issuance of 2,500,000,000 shares of common stock, par value $0.01 per share, and 100,000,000 shares of preferred stock, par value $0.01 per share. The shares of preferred stock have rights and preferences, including voting rights, designated from time to time by the Board of Directors. In connection with the amendment and restatement of the Company's certificate of incorporation effective on the IPO date, the Class A common stock shares were automatically reclassified as, and became, one share of common stock. There were 174,667,840 and 172,108,240 common stock shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively.

**15. Retirement Plans**

We maintain qualified 401(k) plans which cover substantially all employees meeting certain eligibility requirements. Participants may contribute a portion of their compensation to the plans, up to the maximum amount permitted under Section 401(k) of the Internal Revenue Code. Under these plans, we contribute various percentages of employees' salaries to the plans. Total expenses included in operating expenses in the accompanying consolidated statement of operations related to the plans were $1.3 million and $1.1 million for the three months ended September 30, 2025 and 2024 and $3.9 million and $3.6 million for the nine months ended September 30, 2025 and 2024, respectively.

**16. Stock-based Compensation**

*Equity incentive plans*

On October 22, 2019, the Board of Directors approved the Waystar Holding Corp. 2019 Stock Incentive Plan ("2019 Waystar Holding Plan"). Under this plan, we can issue up to 9.9 million options or other equity awards. The granted awards contain service criteria, performance criteria, market conditions, or a combination thereof for vesting and have a 10-year contractual term. Options with a service condition generally vest over 5 years with 20% vesting in equal vesting installments. Options with a performance condition and a market condition vest based upon a change in control, initial public offering, or a sponsor distribution or deemed return if the investors have achieved specified levels of return on investment. In addition, as part of a change in control in 2019, 2.2 million fully vested rollover options remain outstanding.

The Board of Directors approved the Waystar Holding Corp. 2024 Equity Incentive Plan (the "2024 Equity Incentive Plan"), effective as of June 6, 2024, the date of pricing of our IPO. Under this plan, we can issue non-qualified stock options, incentive stock options, stock appreciation rights, restricted shares of the Company's Common Stock, restricted stock units, performance based stock units, and other equity-based awards tied to the value of the Company's shares. Under this plan, we can issue up to 10 million options and other equity awards, subject to annual increases as outlined under the plan. The number of shares available to be issued automatically increases on the first day of each fiscal year beginning in 2025 by a number of shares equal to the lesser of the positive difference, if any, between 5% of the outstanding common

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

stock on the last day of the immediately preceding fiscal year, minus the plan share reserve on the last day of the immediately preceding fiscal year or such lesser number of shares as may be determined by the Board of Directors. Options with a service condition generally vest over 5 years with 20% vesting in equal vesting installments. The restricted stock units ("RSUs") under the 2024 Equity Incentive Plan generally vest over 4 or 5 years with 25% or 20% vesting, respectively, in equal vesting installments. The performance-based stock units ("PSUs") under the 2024 Equity Incentive Plan vest between 0% and 200% based on the company's total shareholder return ("TSR") relative to a designated peer group as defined in the respective agreement over a four-year performance period. As of September 30, 2025, 5.4 million shares were available for future grants under this plan.

The Board of Directors approved the Waystar Holding Corp. 2024 Employee Stock Purchase Plan (the "ESPP"), effective as of June 6, 2024, the date of pricing of our IPO. A total of 3,250,000 shares of common stock are initially reserved for the ESPP. The number of shares available to be issued for the ESPP will automatically increase each fiscal year beginning in 2025 by a number of shares equal to the lesser of the positive difference, if any, between 1% of the outstanding common stock on the last day of the immediately preceding fiscal year and the number of shares of common stock available for the issuance of shares pursuant to the plan on the last day of the immediately preceding fiscal year or such lesser number of shares as may be determined by the Board of Directors. The number of shares available to be issued for the ESPP will not exceed 27,000,000 as outlined in the plan agreement. Our employees contribute funds via payroll deductions during the offering periods, which are used to buy Waystar common shares at a discount of up to 15% of the purchase price at the purchase date. Offerings to purchase shares are granted twice annually on or about June 30 and December 31. During the three and nine months ended September 30, 2025, 37,323 of common shares have been issued as part of the ESPP. For the three and nine months ended September 30, 2025, expense of $0.1 million and $0.4 million, respectively, has been recorded which represents the 15% discount given to the employees under the ESPP. During the three and nine months ended September 30, 2024, zero expense was recorded related to the 15% discount given to the employees under the ESPP.

*Stock Options*

We utilize the Black-Scholes option pricing model to estimate the fair value of the service condition options under all plans and the Monte Carlo pricing model to estimate the fair value of the performance condition options under the 2019 Waystar Holding Corp. Plan. We value both types of options at the grant date using the following assumptions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Risk-free interest rate—reflects the average rate on the United States Treasury bond with maturity equal to the expected term of the option;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Expected dividend yield—as we do not currently pay dividends or expect to pay dividends in the near future, the expected dividend yield is zero;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Expected term of stock award – under the 2024 Equity Incentive Plan, we utilized the simplified method due to the lack of historical experience activity for Waystar. The simplified method calculates the expected term as the mid-point between the vesting date and the contractual expiration date of the award. Under the 2019 Waystar Holding Corp. Plan, it is based on historical experience that is modified based on expected future changes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Expected volatility in stock price—reflects the historical volatility of comparable public companies over the expected term of the stock option.

The weighted average grant date fair value of options granted during the nine months ended September 30, 2025 was $18.69 per share. No options were granted during the three months ended September 30, 2025. The weighted average grant date fair value of options granted during the nine months ended September 30, 2024 was $12.89 per share. No options were granted during the three months ended September 30, 2024. As of September 30, 2025, we had 6.8 million fully vested options with a weighted average exercise price of $15.03 per share, an aggregate intrinsic value of $156.3 million and an average remaining contractual term of 4.2 years. The total fair value of options vested for the three months ended September 30, 2025 and 2024 were $2.9 million and $2.9 million, respectively and $16.5 million and $4.8 million for the nine months ended September 30, 2025 and 2024, respectively.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

Information pertaining to option activity under all plans (including rollover options) during the nine months ended September 30, 2025 and 2024 is as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Number of<br>options** | **Weighted average<br>exercise price per<br>share** | **Weighted<br>average<br>remaining<br>contractual life** |
| **Outstanding December 31, 2024** | 16511128 | $17.57 | 5.8 |
| Granted | 132065 | 36.94 |  |
| Exercised | (2061626) | 10.14 |  |
| Forfeited | (121202) | 29.75 |  |
| **Outstanding September 30, 2025** | 14460365 | $18.71 | 5.2 |

---

---

| | | | |
|:---|:---|:---|:---|
| | **Number of<br>options** | **Weighted average<br>exercise price per<br>share** | **Weighted<br>average<br>remaining<br>contractual life** |
| **Outstanding December 31, 2023** | 13032541 | $15.20 | 5.7 |
| Granted | 4003703 | 24.20 |  |
| Exercised | (369905) | 4.27 |  |
| Forfeited | (90145) | 20.39 |  |
| **Outstanding September 30, 2024** | 16576194 | $17.59 | 6.1 |

---

The following is a summary of the significant assumptions used in estimating the fair value of options granted the three and nine months ended September 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Risk free interest rate | N/A | N/A | 3.95% | 3.76%-4.59% |
| Expected dividend yield | N/A | N/A | 0% | 0% |
| Expected term of stock award | N/A | N/A | 6.2 | 5.0 - 6.5 |
| Expected volatility in stock price | N/A | N/A | 46.24% | 49.62%-51.89% |

---

The aggregate intrinsic value of options exercised (the difference between the fair market value of our stock on the date of exercise and the exercise price) was approximately $12.8 million and $6.7 million for the three months ended September 30, 2025 and 2024, respectively and $61.7 million and $6.7 million for the nine months ended September 30, 2025 and 2024, respectively.

We expect to incur compensation expense of approximately $41.0 million over a weighted average of 3.4 years for all unvested time-based awards outstanding on September 30, 2025.

*RSUs*

The RSUs granted on June 10, 2024 in conjunction with the IPO were valued at the IPO price. Subsequent RSU grants have been valued using our common stock price as of the grant date based on the publicly traded value per NASDAQ, and are expensed on a straight-line basis over the applicable vesting period. All vesting is contingent on continued service.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

The following table summarizes RSU activity during the nine months ended September 30, 2025 and 2024.

---

| | | |
|:---|:---|:---|
| | **Number of <br>shares** | **Weighted <br>average grant <br>date fair value** |
| **Outstanding December 31, 2024** | 2089241 | $21.91 |
| Granted | 2323495 | 37.34 |
| Vested | (460362) | 21.50 |
| Forfeited | (55819) | 27.40 |
| **Outstanding September 30, 2025** | 3896555 | $31.08 |

---

---

| | | |
|:---|:---|:---|
| | **Number of <br>shares** | **Weighted <br>average grant <br>date fair value** |
| **Outstanding December 31, 2023** |  | $— |
| Granted | 2011651 | 21.50 |
| Vested |  |  |
| Forfeited | (8259) | 21.50 |
| **Outstanding September 30, 2024** | 2003392 | $21.50 |

---

We expect to incur compensation expense of $110.8 million over a weighted average of 4.5 years for all unvested RSUs outstanding on September 30, 2025.

*PSUs*

We utilize the Monte Carlo pricing model to estimate the fair value of the market-based condition PSUs at the grant date under the 2024 Equity Incentive Plan. The Monte Carlo model incorporates assumptions regarding expected volatility, correlation between performance of our stock price and that of publicly traded peer companies, expected dividend yields and the risk-free interest rate. The Monte Carlo pricing model simulates potential future stock price paths yielding a grant date fair value that reflects the likelihood of varying outcomes. These awards are expensed on a straight-line basis over the applicable vesting period utilizing the fair value at the grant date.

The following is a summary of the significant assumptions used in estimating the fair value of PSUs granted during the nine months ended September 30, 2025. There were no PSUs granted during the three months ended September 30, 2025 or during the three and nine months ended September 30, 2024.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Nine Months Ended September 30, 2025** | **Nine Months Ended September 30, 2025** |
| | **2025** | **2024** | **2025** | **2024** |
| Risk free interest rate | N/A | N/A | 3.92% | N/A |
| Expected dividend yield | N/A | N/A | 0% | N/A |
| Expected term of stock award | N/A | N/A | 4.0 | N/A |
| Expected volatility in stock price | N/A | N/A | 40.00% | N/A |

---

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

The following table summarizes PSU activity during the nine months ended September 30, 2025.

---

| | | |
|:---|:---|:---|
| | **Number of <br>shares** | **Weighted <br>average grant <br>date fair value** |
| **Outstanding December 31, 2024** |  | $— |
| Granted | 396197 | 61.67 |
| Vested |  |  |
| Forfeited |  |  |
| **Outstanding September 30, 2025** | 396197 | $61.67 |

---

We expect to incur compensation expense of $21.4 million over a weighted average of 3.5 years for all unvested PSUs outstanding on September 30, 2025.

*Stock-based Compensation*

We recorded $11.6 million and $7.9 million of stock-based compensation expense for the three months ended September 30, 2025 and 2024, respectively and $29.9 million and $47.4 million for the nine months ended September 30, 2025 and 2024, respectively.

Stock-based compensation expense was recorded in the following cost and expense categories in the consolidated statements of operations:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Cost of revenue | $418 | $300 | $1064 | $2161 |
| General and administrative | 7218 | 4832 | 18418 | 27043 |
| Sales and marketing | 2392 | 1587 | 6198 | 10958 |
| Research and development | 1569 | 1184 | 4191 | 7238 |
| Total | $11597 | $7903 | $29871 | $47400 |

---

**17. Other Accrued Expenses**

Other accrued expenses consist of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **December 31, 2024** |
| Accrued income taxes | $13246 | $4111 |
| Other taxes payable | 1214 | 3915 |
| Accrued severance | 300 |  |
| Retirement plan payable | 25 | 497 |
| Accrued self insurance claims | 1909 | 1064 |
| Accrued interest | 272 | 597 |
| Accrued rent | 1609 |  |
| ESPP payable | 994 |  |
| Other | 7188 | 5746 |
| Total | $26757 | $15930 |

---

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

**18. Income/(Loss) Per Share**

A reconciliation of the numerators and the denominators of the basic and diluted per share computations are as follows (in thousands, except for share and per share data):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Basic income/(loss) per share: |  |  |  |  |
| Net income/(loss) | $30648 | $5413 | $92101 | $(38204) |
| Net income/(loss) attributable to common shares | $30648 | $5413 | $92101 | $(38204) |
| Weighted average common stock outstanding–(voting) | 174352079 | 171578311 | 173388077 | 142367458 |
| Basic weighted average common stock outstanding | 174352079 | 171578311 | 173388077 | 142367458 |
| Basic income/(loss) per share | $0.18 | $0.03 | $0.53 | $(0.27) |
| *Diluted income/(loss) per share:* |  |  |  |  |
| Net income/(loss) | $30648 | 5413 | $92101 | (38204) |
| Net income/(loss) attributable to common shares | $30648 | $5413 | $92101 | $(38204) |
| Dilutive effect of stock options – (voting) | 6048579 | 4268993 | 6736352 |  |
| Dilutive effect of RSUs – (voting) | 836036 | 334207 | 1040195 |  |
| Dilutive effect of ESPP – (voting) | 3339 |  | 1113 |  |
| Weighted average common stock outstanding–(voting) | 181240033 | 176181511 | 181165737 | 142367458 |
| Diluted weighted average common stock outstanding | 181240033 | 176181511 | 181165738 | 142367458 |
| Diluted income/(loss) per share | $0.17 | $0.03 | $0.51 | $(0.27) |

---

Because of their anti-dilutive effect, 1,652,397 and 5,247,024 common share equivalents comprised of stock options and RSUs have been excluded from the diluted earnings per share calculation for the three months ended September 30, 2025 and 2024, respectively. Additionally because of their anti-dilutive effect, 1,305,855 and 12,148,217 common share equivalents comprised of stock options and RSUs have been excluded from diluted earnings per share calculation for the nine months ended September 30, 2025 and 2024, respectively.

**19. Commitments and Contingencies**

We may be subject to legal proceedings, claims, asserted or unasserted, and litigation arising in the ordinary course of business. We do not, however, currently expect that the ultimate costs to resolve any pending matter will have a material effect on our consolidated financial position, results of operations, or cash flows.

**20. Subsequent Events**

We have evaluated subsequent events through the date of issuance.

On October 1, 2025, the Company completed the acquisition of Iodine pursuant to the Agreement and Plan of Merger (the "Merger Agreement") entered into on July 23, 2025 for total cash consideration of approximately $458.6 million and 16,639,920 shares of common stock having a value of $37.31 per share as outlined in the Merger Agreement. Due to the timing of the acquisition, the accounting conclusions related to the transaction have not yet been finalized.

On October 1, 2025, we entered into the Twelfth Amendment to the First Lien Credit Agreement to increase our First Lien Credit Facility by $250.0 million, increase the maximum borrowing capacity under the revolving credit facility from $400.0 million to $500.0 million, and decrease the interest rate under the revolving credit facility from 1.75% per annum above SOFR to 1.50% per annum above SOFR. We drew $30.0 million on the revolving credit facility to help fund the Iodine acquisition.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Waystar Holding Corp.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

On October 28, 2025, we reached a settlement agreement to terminate the prior lease on one of our office locations that was relocated in the third quarter of 2024. The total settlement was $15.0 million. Due to the timing of the settlement, the accounting conclusions related to the transaction have not yet been finalized.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion and analysis of Waystar Holding Corp. ("Waystar", the "Company", "we", "us", and "our") financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and the related notes included elsewhere in this Form 10-Q, and the consolidated financial statements and related notes included in the 2024 Form 10-K. In addition to historical information, this discussion and analysis contains forward-looking statements based on current expectations that involve risks, uncertainties, and other factors outside the Company's control, as well as assumptions, such as our plans, objectives, expectations, and intentions. Our actual results may differ materially from those expressed or implied in the forward-looking statements as a result of various factors, including those described under the sections entitled "Cautionary Statement Concerning Forward-Looking Statements" above and "Risk Factors" in the 2024 Form 10-K and our other filings with the SEC.*

**Overview**

Waystar provides healthcare organizations with mission-critical cloud software that simplifies healthcare payments. Our enterprise-grade platform streamlines the complex and disparate processes our healthcare provider clients must manage to be reimbursed correctly, while improving the payments experience for providers, patients, and payers. We leverage AI as well as proprietary, advanced algorithms to automate payment-related workflow tasks and drive continuous improvement, which enhances claim and billing accuracy, enriches data integrity, and reduces labor costs for providers.

Our software is used daily by providers of all types and sizes across the continuum of care, including physician practices, clinics, surgical centers, and laboratories, as well as large hospitals and health systems. We currently serve over 30,000 clients of various sizes, representing over one million distinct providers practicing across a variety of care sites, including 17 of the top 20 U.S. News Best Hospitals. Our business model is designed such that as our clients grow to serve more patients, their claims and transactional volumes increase, resulting in corresponding growth in our business. In addition, our clients frequently adopt a greater number of our solutions over time and introduce our solutions across new sites of care. In 2024, we facilitated over six billion healthcare payments transactions, including over $1.8 trillion in gross claims volume. As of 2024, we facilitated healthcare payments transactions spanning approximately 50% of patients in the United States.

Our platform benefits from powerful network effects. Our cloud-based software is driven by a sophisticated, automated, and curated rules engine, employing AI to generate and incorporate real-time feedback from millions of network transactions processed through our platform each day. Every transaction we process provides additional data insights across providers, patients, and payers, which are embedded in updates that are deployed efficiently across our client base. This results in cumulative benefits to us over time —as we capture more data from each transaction we process, we leverage that data to continue to improve the Waystar platform through embedded machine learning, advanced algorithms, and other in-house AI technologies to deliver added value to our clients. In turn, the more value we create for our clients, the more likely it is that they will continue to use our products, allowing us to continue to capture more data that results in tangible improvements to our platform. As a result, our clients benefit from faster and more efficient performance from software that is evolving to meet ever-changing regulatory and payer requirements, enabling accurate and timely reimbursement.

We have demonstrated an ability to drive recurring, predictable, and profitable growth. Over 99% of our revenue is either recurring subscription or based on highly predictable volumes. For the twelve months ended September 30, 2025, our Net Revenue Retention Rate was 113.1% and we have 1,306 clients as of September 30, 2025 generating over $100,000 over the same twelve month period. For the nine months ended September 30, 2025, we generated revenue of $795.7 million (reflecting a 13.8% increase compared to revenue of $699.4 million for the same period in the prior year), net income of $92.1 million compared to net loss of $38.2 million for the same period in the prior year, and Adjusted EBITDA of $333.0 million (reflecting a 17.5% increase compared to Adjusted EBITDA of $283.3 million for the same period in the prior year).

***Initial Public Offering*** 

In June 2024, we completed an initial public offering (the "IPO") of 45,000,000 shares of common stock at a price of $21.50 per share. After underwriting discounts and commissions of $53.2 million, we received total proceeds from the offering of $914.3 million. On July 5, 2024, pursuant to the option granted to the underwriters for a period of 30 days from the date of the IPO Prospectus to purchase up to 6,750,000 additional shares of common stock from us at the IPO price less the underwriting discount, the underwriters exercised the right to purchase 5,059,010 additional shares of common stock,

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

resulting in additional net proceeds of $102.8 million, after deducting underwriting discounts and commissions of $6.0 million. The remaining option to purchase additional shares expired unexercised at the end of the 30-day period. See Item 1, Financial Statements, Note 1 (Business) in the 2024 Form 10-K for more information.

***Secondary Offerings***

On February 24, 2025, the Institutional Investors closed an underwritten public offering of 23,000,000 shares of our common stock (inclusive of the underwriters' option to purchase additional shares) (the "First Secondary Offering"). On May 15, 2025, the Institutional Investors closed another underwritten public offering of 14,375,000 shares of our common stock (inclusive of the underwriters' option to purchase additional shares) (the "Second Secondary Offering"). Additionally on September 10, 2025, the Institutional Investors closed another underwritten public offering of 18,000,000 shares of our common stock (the "Third Secondary Offering"). The Company did not sell any shares in these offerings or receive any proceeds from these offerings. Pursuant to the terms of the Amended and Restated Registration Rights Agreement, dated as of June 10, 2024, by and among the Company, the Institutional Investors, and certain other parties thereto, we paid $1.4 million and $4.6 million in certain expenses on behalf of the selling stockholders related to these offerings for the three and nine months ended September 30, 2025, respectively, while the selling stockholders paid all applicable underwriting discounts and commissions.

***Iodine Acquisition***

On July 23, 2025, we entered into the Merger Agreement to acquire Iodine through a series of mergers. Iodine is a trusted leader in AI-powered clinical intelligence, enhancing clinical documentation and accuracy, streamlining utilization management, and preventing revenue leakage before billing. This strategic move is expected to bolster our AI leadership, automate manual work, and improve financial performance for providers. The acquisition was completed on October 1, 2025 for a total purchase price of $1.25 billion. The consideration paid was approximately $458.6 million in cash consideration and 16,639,920 shares of common stock having a value of $37.31 per share, and certain adjustments as outlined in the Merger Agreement.

**Significant Items Affecting Comparability**

We believe that the future growth and profitability of our business, and the comparability of our results from period to period, depend on numerous factors, including the following:

***Our Ability to Expand our Relationship with Existing Clients***

As our clients grow their businesses and provide more services and see more patients, our volume-based revenues also increase. In addition, our growth in revenues also depends on our ability to sell more products and solutions to existing clients, including through cross-selling as our clients adopt additional Waystar offerings as well as up-selling as our clients leverage our solutions across additional providers and sites of care.

***Our Ability to Grow our Client Base***

We are focused on continuing to grow our client base, which will depend in part on our ability to continue to maintain our product leadership, invest in our research and development team, and maintain our reputation and brand.

***Impacts of the IPO***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Debt Repayment.* We used proceeds from our IPO to repay an aggregate of $1.0 billion in outstanding principal amount on our First Lien Credit Facility in the second and third quarters of fiscal 2024. This debt repayment has contributed to lower interest expense for the three and nine months ended September 30, 2025 compared to the same periods in the prior year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Stock-Based Compensation Expenses.* We expect to recognize stock-based compensation expense of $17.9 million per year over the applicable vesting periods in connection with equity awards granted in connection with the IPO. Such stock-based compensation expense will be reflected in our results of operations from the closing date of the IPO through the applicable vesting periods of such awards. Additionally, we recognized $33.1 million of stock-based compensation expense during the nine months ended September 30, 2024, as the vesting of our performance

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

condition options became probable upon the closing of the IPO as the implicit service period for the awards established at the grant date had elapsed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Incremental Public Company Expenses.* Following the IPO, we have incurred significant expenses on an ongoing basis that we did not incur as a private company. Those costs include additional director and officer liability insurance expenses, as well as third-party and internal resources related to accounting, auditing, Sarbanes-Oxley Act compliance, legal, and investor and public relation expenses. These costs are generally expensed under general and administrative expenses.

**Components of Results of Operations**

***Revenue***

We primarily generate two types of revenue: (i) subscription revenue and (ii) volume-based revenue, which account for 99% of total revenue for all periods presented. We believe we have high visibility into our volume-based and subscription revenue from existing clients. We refer to the solutions our clients use to better process and understand their payment workflows from payers as provider solutions, and we refer to the products that assist healthcare providers in collecting payments from patients as patient payment solutions. We expect provider solutions will continue to generate the substantial majority of our total revenue, although the revenue mix attributable to patient payment solutions is expected to increase slightly over time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Subscription revenue*. Reflects recurring monthly provider count fees and minimum amounts owed. The vast majority of subscription revenue is generated by provider solutions, which constituted approximately 70% of total revenue in each of the three and nine months ended September 30, 2025 and 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Volume-based revenue*. Represents recurring fees associated with transaction count or dollar volumes in excess of minimums. Generally, approximately half of our volume-based revenue is generated from provider solutions that are based on transaction count, with the other half from patient payments solutions that are based on either dollar volumes or transaction count.

We also derive revenue from implementation fees for our software, as well as hardware sales to facilitate patient payments. Our implementation fees are billed upfront and the revenue is recognized ratably over the customer's life.

***Cost of Revenue (Exclusive of Depreciation and Amortization)***

Cost of revenue includes salaries, stock-based compensation, and benefits ("personnel costs") for our team members who are focused on implementation, support, and other client-focused operations, as well as team members focused on enhancing and developing our platform. Cost of revenue also includes costs for third-party technology such as interchange fees and infrastructure related to the operations of our platform, including communicating and processing patient payments, and services to support the delivery of our solutions. Third-party costs for patient payments solutions are approximately 60% of the revenue generated from these solutions, while third-party costs for provider solutions are approximately 6% to 8% of the associated revenue, in each case, for both the three and nine months ended September 30, 2025 and 2024.

***Sales and Marketing***

Sales and marketing costs consist primarily of personnel costs, internal sales commissions, channel partner fees, travel, and advertising costs.

***General and Administrative***

General and administrative expenses consist of personnel costs incurred in our corporate service functions such as finance expenses, legal, human resources, and information technology, as well as other professional service costs.

***Research and Development***

Research and development costs consist primarily of personnel costs for team members engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred, except for capitalized software development costs.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

***Depreciation and Amortization***

Depreciation and amortization consists of the depreciation of property and equipment and amortization of certain intangible assets, including capitalized software.

***Other Expense***

Other expense consists primarily of interest expense and related-party interest expense, inclusive of the impact of interest rate swaps and net of interest income.

***Income Tax Expense/(Benefit)***

Income tax expense/(benefit) includes current income tax and income tax credits from deferred taxes. Income tax expense/benefit is recognized in profit and loss except to the extent that it relates to items recognized in equity or other comprehensive income, in which case the income tax expense/(benefit) is also recognized in equity or other comprehensive income.

**Results of Operations for the Three Months Ended September 30, 2025 and 2024**

The following table provides consolidated operating results for the periods indicated and percentage of revenue for each line item:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Three months ended September 30,** | **Three months ended September 30,** | | |
| | **2025** | **2025** | **2024** | **2024** | **Change** | **Change** |
|<br>*($ in thousands)* | **($)** | **(%)** | **($)** | **(%)** | **($)** | **(%)** |
| Revenue | $268651 | 100.0% | $240112 | 100.0% | $28539 | 11.9% |
| Operating expenses |  |  |  |  |  |  |
| &nbsp;&nbsp;Cost of revenue (exclusive of depreciation and amortization) | 85136 | 31.7% | 80545 | 33.5% | 4591 | 5.7% |
| &nbsp;&nbsp;Sales and marketing | 45158 | 16.8% | 38450 | 16.0% | 6708 | 17.4% |
| &nbsp;&nbsp;General and administrative | 32422 | 12.1% | 22704 | 9.5% | 9718 | 42.8% |
| &nbsp;&nbsp;Research and development | 12403 | 4.6% | 11082 | 4.6% | 1321 | 11.9% |
| &nbsp;&nbsp;Depreciation and amortization | 33300 | 12.4% | 60185 | 25.1% | (26885) | (44.7)% |
| &nbsp;&nbsp;&nbsp;Total operating expenses | 208419 | 77.6% | 212966 | 88.7% | (4547) | (2.1)% |
| **Income from operations** | 60232 | 22.4% | 27146 | 11.3% | 33086 | 121.9% |
| Other expense |  |  |  |  |  |  |
| &nbsp;&nbsp;Interest expense | (16613) | (6.2)% | (17752) | (7.4)% | 1139 | (6.4)% |
| &nbsp;&nbsp;Related party interest expense | (902) | (0.3)% | (707) | (0.3)% | (195) | 27.6% |
| **Income/(loss) before income taxes** | 42717 | 15.9% | 8687 | 3.6% | 34030 | 391.7% |
| &nbsp;&nbsp;Income tax expense/(benefit) | 12069 | 4.5% | 3274 | 1.4% | 8795 | 268.6% |
| **Net income/(loss)** | $30648 | 11.4% | $5413 | 2.3% | $25235 | 466.2% |

---

*Revenue*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Three months ended September 30,** | **Three months ended September 30,** | | |
| | **2025** | **2025** | **2024** | **2024** | **Change** | **Change** |
|<br>($ in thousands) | **($)** | **(%)** | **($)** | **(%)** | **($)** | **(%)** |
| **Revenue** |  |  |  |  |  |  |
| Subscription revenue | $134450 | 50.0% | $117993 | 49.1% | $16457 | 13.9% |
| Volume-based revenue | 132342 | 49.3% | 120678 | 50.3% | 11664 | 9.7% |
| Services and other revenue | 1859 | 0.7% | 1441 | 0.6% | 418 | 29.0% |
| **Total Revenue** | $268651 | 100.0% | $240112 | 100.0% | $28539 | 11.9% |

---

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

Revenue was $268.7 million for the three months ended September 30, 2025 as compared to $240.1 million for the three months ended September 30, 2024, an increase of $28.5 million, or 11.9%, of which $16.5 million was attributed to subscription revenue from new and existing clients, almost all of which was generated by provider solutions. Another $11.7 million was attributed to volume-based revenue primarily related to expansion of existing client usage, of which $5.7 million was generated by patient payments solutions and $5.9 million was generated by provider solutions.

*Cost of Revenue (Exclusive of Depreciation and Amortization)*

Cost of revenue was $85.1 million for the three months ended September 30, 2025 as compared to $80.5 million for the three months ended September 30, 2024, an increase of $4.6 million, or 5.7%. The increase was primarily driven by $2.1 million in increased costs stemming from higher transaction volumes and associated third-party costs, including higher platform usage of which approximately $4.6 million was third-party costs associated with payment solutions offset by a decrease of $2.4 million from third-party costs associated with provider solutions, primarily from timing of prior acquisition synergy attainment. Additionally, there was a $1.8 million of increased personnel costs, net of capitalization expense.

*Sales and Marketing*

Sales and marketing expense was $45.2 million for the three months ended September 30, 2025 as compared to $38.5 million for the three months ended September 30, 2024, an increase of $6.7 million, or 17.4%. The increase was primarily driven by an increase in channel partner fees and amortization of the internal commission deferred contract costs asset of $3.3 million, increased personnel costs of $1.4 million and increased stock-based compensation costs of $0.8 million.

*General and Administrative*

General and administrative expense was $32.4 million for the three months ended September 30, 2025 as compared to $22.7 million for the three months ended September 30, 2024, an increase of $9.7 million, or 42.8%. The increase was primarily due to an increase in third party professional fees of $7.1 million from acquisition activity, the August 2025 Debt Repricing and secondary offerings during the quarter. Additionally, there was an increase in stock-based compensation expense of $2.4 million.

*Research and Development*

Research and development expense was $12.4 million for the three months ended September 30, 2025 as compared to $11.1 million for the three months ended September 30, 2024, an increase of $1.3 million, or 11.9%. The increase was primarily due to an increase in personnel costs of $0.8 million and an increase in stock-based compensation expense of $0.4 million.

*Depreciation and Amortization*

Depreciation and amortization expense was $33.3 million for the three months ended September 30, 2025, as compared to $60.2 million for the three months ended September 30, 2024, a decrease of $26.9 million, or 44.7%. The decrease was due to several intangible assets becoming fully amortized in the prior year, driving a decrease in intangible amortization.

*Interest Expense*

Total interest expense was $17.5 million for the three months ended September 30, 2025 as compared to $18.5 million for the three months ended September 30, 2024, a decrease of $0.9 million, or 5.1%. The slight decrease was primarily attributable to debt repricings associated with the First Lien Credit Facility executed in December 2024 and August 2025 partially offset by a favorable interest rate swap that matured in October 2024.

*Income Tax Expense/(Benefit)*

Income tax expense was $12.1 million for the three months ended September 30, 2025, as compared to an income tax expense of $3.3 million for the three months ended September 30, 2024, an increase of $8.8 million. The increase was primarily driven by the increase in pre-tax income/(loss).

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Results of Operations for the Nine Months Ended September 30, 2025 and 2024**

The following table provides consolidated operating results for the periods indicated and percentage of revenue for each line item:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Nine months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** | | |
| | **2025** | **2025** | | **2024** | **2024** | **Change** | **Change** |
| *($ in thousands)* | **($)** | **(%)** |  | **($)** | **(%)** | **($)** | **(%)** |
| Revenue | $795740 | 100.0% |  | $699447 | 100.0% | $96293 | 13.8% |
| Operating expenses |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Cost of revenue (exclusive of depreciation and amortization) | 255525 | 32.1% |  | 236188 | 33.8% | 19337 | 8.2% |
| &nbsp;&nbsp;Sales and marketing | 128805 | 16.2% |  | 117945 | 16.9% | 10860 | 9.2% |
| &nbsp;&nbsp;General and administrative | 84914 | 10.7% |  | 88794 | 12.7% | (3880) | (4.4)% |
| &nbsp;&nbsp;Research and development | 36103 | 4.5% |  | 37303 | 5.3% | (1200) | (3.2)% |
| &nbsp;&nbsp;Depreciation and amortization | 100106 | 12.6% |  | 148635 | 21.3% | (48529) | (32.6)% |
| &nbsp;&nbsp;&nbsp;Total operating expenses | 605453 | 76.1% | ` | 628865 | 89.9% | (23412) | (3.7)% |
| **Income from operations** | 190287 | 23.9% |  | 70582 | 10.1% | 119705 | 169.6% |
| Other expense |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Interest expense | (52195) | (6.6)% |  | (122759) | (17.6)% | 70564 | (57.5)% |
| &nbsp;&nbsp;Related party interest expense | (2475) | (0.3)% |  | (3425) | (0.5)% | 950 | (27.7)% |
| **Income/(loss) before income taxes** | 135617 | 17.0% |  | (55602) | (7.9)% | 191219 | (343.9)% |
| &nbsp;&nbsp;Income tax expense/(benefit) | 43516 | 5.5% |  | (17398) | (2.5)% | 60914 | (350.1)% |
| **Net income/(loss)** | $92101 | 11.6% |  | $(38204) | (5.5)% | $130305 | (341.1)% |

---

*Revenue*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Nine months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** | | |
| | **2025** | **2025** | **2024** | **2024** | **Change** | **Change** |
|<br>*($ in thousands)* | **($)** | **(%)** | **($)** | **(%)** | **($)** | **(%)** |
| **Revenue** |  |  |  |  |  |  |
| Subscription revenue | $390599 | 49.1% | $336421 | 48.1% | $54178 | 16.1% |
| Volume-based revenue | 400551 | 50.3% | 358723 | 51.3% | 41828 | 11.7% |
| Services and other revenue | 4590 | 0.6% | 4303 | 0.6% | 287 | 6.7% |
| **Total Revenue** | $795740 | 100.0% | $699447 | 100.0% | $96293 | 13.8% |

---

Revenue was $795.7 million for the nine months ended September 30, 2025 as compared to $699.4 million for the nine months ended September 30, 2024, an increase of $96.3 million, or 13.8%, of which $54.2 million was attributed to subscription revenue from new and existing clients, almost all of which is generated by provider solutions. Another $41.8 million was attributed to volume-based revenue primarily related to expansion of existing client usage, most of which was generated by patient payments solutions.

*Cost of Revenue (Exclusive of Depreciation and Amortization)*

Cost of revenue was $255.5 million for the nine months ended September 30, 2025 as compared to $236.2 million for the nine months ended September 30, 2024, an increase of $19.3 million, or 8.2%. The increase was primarily driven by $13.9 million in increased costs stemming from higher transaction volume and associated third-party costs, including higher platform usage, of which approximately $20.1 million was third-party costs associated with payment solutions offset by a decrease of $6.2 million from third-party costs associated with provider solutions, primarily from timing of prior acquisition synergy attainment. Additionally, there was an increase in personnel costs, net of capitalization expenses, of $5.8 million.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

*Sales and Marketing*

Sales and marketing expense was $128.8 million for the nine months ended September 30, 2025 as compared to $117.9 million for the nine months ended September 30, 2024, an increase of $10.9 million, or 9.2%. The increase was primarily driven by an increase in channel partner fees and amortization of the internal commission deferred contract costs asset of $11.3 million associated with revenue growth.

*General and Administrative*

General and administrative expense was $84.9 million for the nine months ended September 30, 2025 as compared to $88.8 million for the nine months ended September 30, 2024, a decrease of $3.9 million, or 4.4%. The decrease was primarily due to a reduction in stock-based compensation expense of $8.6 million attributable to the recognition of performance condition options that did not recur during the nine months ended September 30, 2025 (see "Impacts of IPO" section above) partially offset by an increase in personnel costs of $3.9 million.

*Research and Development*

Research and development expense was $36.1 million for the nine months ended September 30, 2025 as compared to $37.3 million for the nine months ended September 30, 2024, a decrease of $1.2 million, or 3.2%. The decrease was primarily driven by a decrease in stock-based compensation expense of $3.0 million attributable to the recognition of performance condition options that did not recur during the nine months ended September 30, 2025 (see "Impacts of IPO" section above) partially offset by an increase in personnel costs, net of capitalization expenses of $1.8 million.

*Depreciation and Amortization*

Depreciation and amortization expense was $100.1 million for the nine months ended September 30, 2025, as compared to $148.6 million for the nine months ended September 30, 2024, a decrease of $48.5 million, or 32.6%. The decrease was due to several intangible assets becoming fully amortized in the prior year, driving a decrease in intangible amortization.

*Interest Expense*

Total interest expense was $54.7 million for the nine months ended September 30, 2025 as compared to $126.2 million for the nine months ended September 30, 2024, a decrease of $71.5 million, or 56.7%. The decrease was driven by the paydowns during 2024 totaling $1.0 billion on our First Lien Credit Facility decreasing the corresponding interest expense.

*Income Tax Benefit*

Income tax expense was $43.5 million for the nine months ended September 30, 2025 as compared to an income tax benefit of $17.4 million for the nine months ended September 30, 2024, an increase of $60.9 million. The increase was primarily driven by the increase in pre-tax income/(loss).

**Non-GAAP Financial Measures**

We present adjusted EBITDA, adjusted EBITDA margin, non-GAAP net income/(loss), and non-GAAP net income/(loss) per share as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP. We believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes these non-GAAP financial measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate, and capital investments. Management uses these to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation, and to compare our performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone provide.

Adjusted EBITDA, adjusted EBITDA margin, non-GAAP net income/(loss), and non-GAAP net income/(loss) per share are not recognized terms under GAAP and should not be considered as an alternative to net income (loss) or net income (loss) margin as measures of financial performance or cash provided by operating activities as a measure of liquidity, or

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

any other performance measure derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management's discretionary use, as they do not consider certain cash requirements such as interest payments, tax payments, and debt service requirements. The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. A reconciliation is provided below for our non-GAAP financial measures to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

***Adjusted EBITDA and Adjusted EBITDA Margin***

We define adjusted EBITDA as net income/(loss) before interest expense, net, income tax expense/(benefit), depreciation and amortization, and as further adjusted for stock-based compensation expense, acquisition and integration costs, asset and lease impairments, costs related to amended debt agreements, and costs related to our IPO and the Secondary Offerings. Adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.

The following table presents a reconciliation of net income/(loss) to adjusted EBITDA and net income/(loss) margin to adjusted EBITDA margin for the three and nine months ended September 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>*($ in thousands)* | **2025** | **2024** | **2025** | **2024** |
| Net income/(loss) | $30648 | $5413 | $92101 | $(38204) |
| &nbsp;&nbsp;Interest expense | 17515 | 18459 | 54670 | 126184 |
| &nbsp;&nbsp;Income tax expense/(benefit) | 12069 | 3274 | 43516 | (17398) |
| &nbsp;&nbsp;Depreciation and amortization | 33300 | 60185 | 100106 | 148635 |
| &nbsp;&nbsp;Stock-based compensation expense | 11597 | 7903 | 29871 | 47400 |
| &nbsp;&nbsp;Acquisition and integration costs | 5313 | 188 | 6197 | 696 |
| &nbsp;&nbsp;Costs related to amended debt agreements | 649 | 106 | 649 | 12876 |
| &nbsp;&nbsp;IPO related and Secondary Offering expenses | 1372 | 109 | 4571 | 2114 |
| &nbsp;&nbsp;Other (a) | 240 | 1040 | 1320 | 1040 |
| &nbsp;&nbsp;Adjusted EBITDA | $112703 | $96677 | $333001 | $283343 |
| &nbsp;&nbsp;Revenue | $268651 | $240112 | $795740 | $699447 |
| &nbsp;&nbsp;Net income/(loss) margin | 11.4% | 2.3% | 11.6% | (5.5)% |
| &nbsp;&nbsp;Adjusted EBITDA margin | 42.0% | 40.3% | 41.8% | 40.5% |

---

_______________________________________________________________

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Adjustments relate to additional lease costs due to the relocation of our Louisville office totaling $0.2 million and $0.7 million, respectively, and executive severance totaling $0.0 million and $0.6 million, respectively, for the three and nine months ended September 30, 2025. For the three and nine months ended September 30, 2024, adjustments relate to additional lease costs due to the relocation of our Louisville office.

***Non-GAAP Net Income/(Loss) and Non-GAAP Net Income/(Loss) Per Share***

We define non-GAAP net income as GAAP net income/(loss) excluding the impact of stock-based compensation, acquisition and integration costs, asset and lease impairments, costs related to our IPO, and the Secondary Offerings, and costs related to amended debt agreements and amortization of intangibles. The tax effects of the adjustments are calculated using a management estimated annual effective non-GAAP tax rate of 21%, which is based on our statutory federal tax rate and provides consistency across interim reporting periods by eliminating the effects of non-recurring and period specific items. Due to the differences in the tax treatment of items excluded from non-GAAP net income, our estimated tax rate on non-GAAP net income may differ from our GAAP tax rate.

Non-GAAP net income per share is shown on both a basic and diluted basis and is defined as non-GAAP net income divided by the basic or diluted weighted-average shares, respectively.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

The following table presents a reconciliation of net loss to non-GAAP net income/(loss) and non-GAAP net income/(loss) per share for the three and nine months ended September 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>($ in thousands) | **2025** | **2024** | **2025** | **2024** |
| Net income/(loss) | $30648 | $5413 | $92101 | $(38204) |
| Stock based compensation | 11597 | 7903 | 29871 | 47400 |
| Acquisition and integration costs | 5313 | 188 | 6197 | 696 |
| Costs related to amended debt agreements | 649 | 106 | 649 | 12876 |
| IPO and Secondary Offering expenses | 1372 | 109 | 4571 | 2114 |
| Other (a) | 240 | 16816 | 1320 | 16816 |
| Intangible amortization | 27851 | 39080 | 84081 | 117240 |
| Tax effect of adjustments | (9875) | (13482) | (26605) | (41400) |
| Non-GAAP net income/(loss) | $67795 | $56133 | $192185 | $117538 |
| Non-GAAP net income/(loss) per share: |  |  |  |  |
| Basic | $0.39 | $0.33 | $1.11 | $0.83 |
| Diluted | $0.37 | $0.32 | $1.06 | $0.80 |
| Weighted-average shares outstanding: |  |  |  |  |
| Basic | 174352079 | 171578311 | 173388077 | 142367458 |
| Diluted | 181240033 | 176181511 | 181165738 | 146843861 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Adjustments relate to additional lease costs due to the relocation of our Louisville office totaling $0.2 million and $0.7 million, respectively, and executive severance totaling $0.0 million and $0.6 million, respectively, for the three and nine months ended September 30, 2025. For the three and nine months ended September 30, 2024, adjustments relate to additional lease costs due to the relocation of our Louisville office.

**Key Performance Metrics**

***Net Revenue Retention Rate***

We also regularly monitor and review our Net Revenue Retention Rate.

The following table presents our Net Revenue Retention Rate for September 30, 2025 and 2024, respectively:

---

| | | |
|:---|:---|:---|
| | **Twelve months ended September 30,** | **Twelve months ended September 30,** |
| *($in thousands)* | **2025** | **2024** |
| Net Revenue Retention Rate | 113.1% | 109.4% |

---

Our Net Revenue Retention Rate compares twelve months of client invoices for our solutions at two period end dates. To calculate our Net Revenue Retention Rate, we first accumulate the total amount invoiced during the twelve months ending with the prior period-end, or Prior Period Invoices. We then calculate the total amount invoiced to those same clients for the twelve months ending with the current period-end, or Current Period Invoices. Current Period Invoices are inclusive of upsell, downsell, pricing changes, clients that cancel or chose not to renew, and discontinued solutions with continuing clients. The Net Revenue Retention Rate is then calculated by dividing the Current Period Invoices by the Prior Period Invoices. Our total invoices included in the analysis are greater than 98% of reported revenue. We use Net Revenue Retention Rate to evaluate our ongoing operations and for internal planning and forecasting purposes. Acquired businesses are included in the last-twelve month Net Revenue Retention Rate in the ninth quarter after acquisition, which is the earliest point that comparable post-acquisition invoices are available for both the current and prior twelve-month period.

***Customer Count with >$100,000 Revenue***

We also regularly monitor and review our count of clients who generate more than $100,000 of revenue.

The following table sets forth our count of clients who generate more than $100,000 of revenue for the periods presented:

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

---

| | | |
|:---|:---|:---|
| | **Twelve months ended September 30,** | **Twelve months ended September 30,** |
| | **2025** | **2024** |
| Customer Count with > $100,000 Revenue | 1306 | 1173 |

---

Our count of clients who generate more than $100,000 of revenue is based on an accumulation of the amounts invoiced to clients over the preceding twelve months. The invoices for acquired clients are included starting in the first full calendar quarter after the date of acquisition.

**Liquidity and Capital Resources**

***Overview***

We assess our liquidity in terms of our ability to generate adequate amounts of cash to meet current and future needs. Our expected primary uses on a short-term and long-term basis are for working capital, capital expenditures, debt service requirements, and investments in future growth, including acquisitions. We have historically funded our operations and acquisitions through our cash and cash equivalents, cash flows from operations, and debt financings. We believe that our existing unrestricted cash on hand, expected future cash flows from operations, and additional borrowings will provide sufficient resources to fund our operating requirements, as well as future capital expenditures, debt service requirements, and investments in future growth for at least the next 12 months. To the extent additional funds are necessary to meet our long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of additional indebtedness, additional equity financings, or a combination of these potential sources of funds. In the event that we need access to additional cash, we may not be able to access the credit markets on commercially acceptable terms or at all. Our ability to fund future operating expenses and capital expenditures and our ability to meet future debt service obligations or refinance our indebtedness will depend on our future operating performance, which will be affected by general economic, financial, and other factors beyond our control, including those described under "Risk factors" in the 2024 Form 10-K.

On September 30, 2025 and December 31, 2024, we had restricted cash of $24.3 million and $22.4 million, respectively, which consists of cash deposited in lockbox accounts owned by us which are contractually required to be disbursed to participating clients on the following day, as well as cash collected on behalf of healthcare providers from patients that have not yet been remitted to providers. These funds payable are not available for our use and liquidity, and are offset on our balance sheet by an aggregated funds payable liability.

On October 1, 2025, we paid approximately $458.6 million in cash in respect of the cash component of the merger consideration for our acquisition of Iodine. On October 1, 2025, we also entered into the Twelfth Amendment to the First Lien Credit Agreement to increase our First Lien Credit Facility by $250.0 million, increase the maximum borrowing capacity under the revolving credit facility from $400.0 million to $500.0 million, and decrease the interest rate under the revolving credit facility from 1.75% per annum above SOFR to 1.50% per annum above SOFR. We drew $30.0 million on the revolving credit facility to help fund the Iodine acquisition.

Our liquidity is influenced by many factors, including timing of revenue and corresponding cash collections, the amount and timing of investments in strategic initiatives, our investments in property, equipment, and software, as well as other factors described under "Risk factors" in the 2024 Form 10-K. Depending on the severity and direct impact of these factors on us, we may not be able to secure additional financing on acceptable terms, or at all.

***Cash Flows***

Cash flows from operating, investing, and financing activities for the nine months ended September 30, 2025 and September 30, 2024, are summarized in the following table:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Nine months ended September 30,** | **Nine months ended September 30,** | **Change** | **Change** |
|<br>*($ in thousands)* | **2025** | **2024** | **Amount** | **Change** |
| Net cash provided by operating activities | $243039 | $104998 | $138041 | 131.5% |
| Net cash used in investing activities | (17069) | (21044) | 3975 | (18.9)% |
| Net cash provided by financing activities | 14805 | 14965 | (160) | (1.1)% |
| Net increase in cash and restricted cash | $240775 | $98919 | $141856 | 143.4% |

---

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

***Cash Flows Provided by Operating Activities***

Cash flows provided by operating activities were $243.0 million for the nine months ended September 30, 2025 as compared to $105.0 million for the nine months ended September 30, 2024, an increase of $138.0 million. This increase is largely driven by changes in working capital, increases in revenue and profits, and decreases in cash paid for interest due to multiple paydowns on our First Lien Credit Facility in 2024.

***Cash Flows Used in Investing Activities***

Cash flows used in investing activities were $17.1 million for the nine months ended September 30, 2025 as compared to $21.0 million for the nine months ended September 30, 2024 a decrease of cash used of $4.0 million. Cash flows used in investing activities decreased due to less purchases of property and equipment during the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024.

***Cash Flows Provided By Financing Activities***

Cash flows provided by financing activities were $14.8 million for the nine months ended September 30, 2025 as compared to $15.0 million for the nine months ended September 30, 2024, a decrease of $0.2 million. The net cash provided in 2024 was driven by proceeds from last year's IPO, net of underwriting discounts and the corresponding paydown on debt, as well as proceeds from the issuance of debt, net of creditor fees, during the nine months ended September 30, 2024. The net cash provided in 2025 was from proceeds from the exercise of stock options during the nine months ended September 30, 2025.

***Indebtedness***

Refer to Item 1, Financial Statements, Notes 11 (Accounts Receivable Securitization) and 12 (Debt), for a description of our Credit Facilities.

**Critical Accounting Policies and Estimates**

The above discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, and expenses, and disclosures of contingent assets and liabilities. Critical accounting policies are those that we consider to be the most important in portraying our financial condition and results of operations and also require the greatest amount of judgments by management. Judgments or uncertainties regarding the application of these policies may result in materially different amounts being reported under different conditions or using different assumptions.

There have been no material changes to our critical accounting policies and estimates from those disclosed in the 2024 Form 10-K.

**Recent Accounting Pronouncements**

Refer to Item 1, Financial Statements, Note 2 (Summary of Significant Accounting Policies).

**JOBS Act Election**

We are currently an "emerging growth company," as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

We are exposed to certain market risks arising from transactions in the normal course of our business. Such risks are principally associated with credit risk and interest rate risk.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

***Credit Risk***

Credit risk involves the possibility that a counterparty will not meet its obligations under a financial instrument or client contract, leading to a financial loss. Concentrations of credit risk with respect to our clients are limited due to our diversified client base.

We routinely assess the financial strength of our clients through a combination of third-party financial reports, credit monitoring, publicly available information, and direct communication with those clients. We establish payment terms with clients to mitigate credit risk and monitor its accounts receivable credit risk exposure. However, while we actively seek to ensure credit risk, there can be no assurance that in the future it will be able to obtain credit risk insurance at commercially attractive terms or at all.

***Interest Rate Risk***

Our exposure to interest rate risk is related to our First Lien Credit Facility, which bears interest at SOFR plus 2.00% as of September 30, 2025. A hypothetical 100 basis point increase or decrease in the current effective rate would have an impact on our interest expense of approximately $3.2 million for the three months ended September 30, 2025 or $9.4 million for the nine months ended September 30, 2025.

In order to limit exposure to risk, we maintain derivative instruments with creditworthy institutions to hedge against changing interest rate fluctuations. We utilize interest rate swap contracts and other non-derivative hedging instruments to manage such risk.

**Item 4. Controls and Procedures**

**Disclosure Controls and Procedures**

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of such date. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to management including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

**Changes in Internal Control Over Financial Reporting**

There were no changes to our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the quarter ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Part II - Other Information**

**Item 1. Legal Proceedings**

The information required with respect to this Part II, Item 1 can be found under Item 1, Financial Statements, Note 19 (Commitments and Contingencies), to the unaudited consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

**Item 1A. Risk Factors**

There have been no material changes to the risk factors disclosed in the 2024 Form 10-K.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

On August 24, 2025, Eric Lee (Ric) Sinclair III, our Chief Business Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Mr. Sinclair's plan provides for (i) the exercise of up to 90,750 vested stock options and the associated sale of up 90,750 shares of the Company's common stock; (ii) the exercise of vested stock options and the associated sale shares of the Company's common stock with the actual number of such options and associated shares to be determined based on unsold shares from Mr. Sinclair's previously adopted trading plan dated February 19, 2025; and (iii) the exercise of options subject to performance-based vesting conditions and the associated sale of shares of the Company's common stock, with the actual number of such options and associated shares to be determined based on the level of achievement of the performance criteria associated with the award. Mr. Sinclair's trading plan will expire December 31, 2026, or upon the earlier sale of all the shares subject to the plan.

On September 9, 2025, Craig Bridge, our Chief Transformation Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Mr. Bridge's plan provides for (i) the exercise of up to 112,485 vested stock options and the associated sale of up 112,485 shares of the Company's common stock; (ii) the exercise of vested stock options and the associated sale shares of the Company's common stock with the actual number of such options and associated shares to be determined based on unsold shares from Mr. Bridge's previously adopted trading plan dated November 27, 2024; and (iii) the exercise of options subject to performance-based vesting conditions and the associated sale of shares of the Company's common stock, with the actual number of such options and associated shares to be determined based on the level of achievement of the performance criteria associated with the award. . Mr. Bridge's trading plan will expire December 31, 2026, or upon the earlier sale of all the shares subject to the plan.

On September 11, 2025, Melissa Miller, our Chief Marketing Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Ms. Miller's plan provides for (i) the exercise of up to 101,470 vested stock options and the associated sale of up 101,470 shares of the Company's common stock; and (ii) the exercise of options subject to performance-based vesting conditions and the associated sale of shares of the Company's common stock, with the actual number of such options and associated shares to be determined based on the level of achievement of the performance criteria associated with the award. Ms. Miller's trading plan will expire December 31, 2026, or upon the earlier sale of all the shares subject to the plan.

On September 11, 2025, Steven Oreskovich, our Chief Financial Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Mr. Oreskovich's plan provides for (i) the exercise of up to 519,277 vested stock options and the associated sale of up 519,277 shares of the Company's common stock; and (ii) the exercise of options subject to performance-based vesting conditions and the associated sale of shares of the Company's common stock, with the actual number of such options and associated shares to be determined based on the

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

level of achievement of the performance criteria associated with the award. Mr. Oreskovich's trading plan will expire December 31, 2026, or upon the earlier sale of all the shares subject to the plan.

On September 11, 2025, Christopher Schremser, our Chief Technology Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Mr. Schremser's plan provides for (i) the exercise of up to 454,682 vested stock options and the associated sale of up 454,682 shares of the Company's common stock; and (ii) the exercise of options subject to performance-based vesting conditions and the associated sale of shares of the Company's common stock, with the actual number of such options and associated shares to be determined based on the level of achievement of the performance criteria associated with the award. Mr. Schremser's trading plan will expire December 31, 2026, or upon the earlier sale of all the shares subject to the plan.

During the nine months ended September 30, 2025, none of the Company's other directors or officers adopted, modified, or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" as each term is defined in Item 408 of Regulation S-K.

**Item 6. Exhibits**

---

| | | |
|:---|:---|:---|
| **Exhibit<br>Number** | **Exhibit Description** | **Filed<br>Herewith** |
| 2.1 | <u>[Agreement and Plan of Merger, dated as of July 23, 2025, by and among Waystar Holding Corp., Morton Merger Sub 1, Inc., Isotope Holding, LLC, Iodine Software Holdings, Inc., Iodine Software Parent, LLC and Shareholder Representative Services LLC, as the equityholder representative (incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed on July 23, 2025](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex2-1.htm)</u> |  |
| 3.2 | <u>[Certificate of Amendment of Amended and Restated Certificate of Incorporation of Waystar Holding Corp. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on June 5, 2025).](https://www.sec.gov/Archives/edgar/data/1990354/000110465925056893/tm2517226d1_ex3-1.htm)</u> |  |
| 3.3 | <u>[Amended and Restated Bylaws of Waystar Holding Corp. (incorporated by reference to Exhibit 4.2 to the Company's Registration Statement on Form S-8 filed on June 10, 2024).](https://www.sec.gov/Archives/edgar/data/1990354/000110465924070058/tm2333808d17_ex4-2.htm)</u> |  |
| 10.1† | <u>[Amendment No.](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-2.htm)[2](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-2.htm)[to the Stockholders Agreement among Waystar Holding Corp. and the other parties named therein, dated as of](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-2.htm)[July 23](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-2.htm)[, 2025 (incorporated by reference to Exhibit 10.](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-2.htm)[2](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-2.htm)[to the Company's](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-2.htm)[Current](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-2.htm)[Report on Form](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-2.htm)[8-K](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-2.htm)[filed on](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-2.htm)[July](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-2.htm)[2](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-2.htm)[3](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-2.htm)[, 2025).](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-2.htm)</u> |  |
| 10.2 | <u>[Stockholder and Lockup Agreement among Waystar Holding Corp., AIO Holdings LP, William Chan and the other parties named therein, dated as of July 23, 2025](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-1.htm)[(incorporated by reference to Exhibit 10.](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-1.htm)[1](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-1.htm)[to the Company's Current Report on Form 8-K filed on July 23, 2025).](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-1.htm)</u> |  |
| 10.3 | <u>[Joinder Agreement to Amended and Restated Registration Rights Agreement, dated as of July 23, 2025](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-3.htm)[(incorporated by reference to Exhibit 10.](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-3.htm)[3](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-3.htm)[to the Company's Current Report on Form 8-K filed on July 23, 2025).](https://www.sec.gov/Archives/edgar/data/1990354/000110465925070034/tm2521498d1_ex10-3.htm)</u> |  |
| 10.4 | <u>[Eleventh Amendment, dated as of August 12, 2025, to the First Lien Credit Agreement, among BNVC Holdings, Inc. (as successor to Derby Parent, Inc.), Waystar Technologies, Inc.(f/k/a Navicure, Inc.) (as successor to Derby Merger Sub, Inc. and BNVC Group Holdings, Inc.), JPMorgan Chase Bank, N.A., as Administrative Agent, Collateral Agent, and Issuing Bank, Barclays Bank PLC as Issuing Bank, Deutsche Bank AG New York Branch, as Issuing Bank, and each lender from time to time party thereto (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on August 12, 2025).](https://www.sec.gov/Archives/edgar/data/1990354/000199035425000015/waystar-eleventhamendmentx.htm)</u> |  |

---

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

---

| | | |
|:---|:---|:---|
| 10.5 | <u>[Twelfth](https://www.sec.gov/Archives/edgar/data/1990354/000110465925095372/tm2527690d1_ex10-1.htm)[Amendment, dated as of](https://www.sec.gov/Archives/edgar/data/1990354/000110465925095372/tm2527690d1_ex10-1.htm)[October](https://www.sec.gov/Archives/edgar/data/1990354/000110465925095372/tm2527690d1_ex10-1.htm)[1](https://www.sec.gov/Archives/edgar/data/1990354/000110465925095372/tm2527690d1_ex10-1.htm)[, 2025, to the First Lien Credit Agreement, among BNVC Holdings, Inc. (as successor to Derby Parent, Inc.), Waystar Technologies, Inc.(f/k/a Navicure, Inc.) (as successor to Derby Merger Sub, Inc. and BNVC Group Holdings, Inc.), JPMorgan Chase Bank, N.A., as Administrative Agent, Collateral Agent, and Issuing Bank, Barclays Bank PLC as Issuing Bank, Deutsche Bank AG New York Branch, as Issuing Bank, and each lender from time to time party thereto (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on](https://www.sec.gov/Archives/edgar/data/1990354/000110465925095372/tm2527690d1_ex10-1.htm)[October](https://www.sec.gov/Archives/edgar/data/1990354/000110465925095372/tm2527690d1_ex10-1.htm)[1](https://www.sec.gov/Archives/edgar/data/1990354/000110465925095372/tm2527690d1_ex10-1.htm)[, 2025).](https://www.sec.gov/Archives/edgar/data/1990354/000110465925095372/tm2527690d1_ex10-1.htm)</u> |  |
| 31.1 | <u>[Certification of Chief Executive Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](way093025-ex311.htm)</u> | X |
| 31.2 | <u>[Certification of Chief Financial Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](way093025-ex312.htm)</u> | X |
| 32.1 \* | <u>[Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](way093025-ex321.htm)</u> | X |
| 32.2 \* | <u>[Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](way093025-ex322.htm)</u> | X |
| 101.INS | XBRL Instance Document - the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document. | X |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | X |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | X |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | X |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | X |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | X |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | X |

---

_______________________________________________________________

XFiled Herewith

† Management contract or compensatory plan or arrangement.

\*This exhibit shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such exhibit shall not be deemed incorporated into any filing under the Securities Act or the Exchange Act.

The agreements and other documents filed as exhibits to this report are not intended to provide factual information or other disclosure other than the terms of the agreements or other documents themselves, and you should not rely on them for that purpose. In particular, any representations and warranties made by the Company in these agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs as of the date they were made or at any other time.

------

<u>[**Table of Contents**](#i17c1154a7f494eb98665b6e2e67bcada_10)</u>

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lehi, Utah, on October 29, 2025.

---

| | | |
|:---|:---|:---|
| **WAYSTAR HOLDING CORP.** | **WAYSTAR HOLDING CORP.** | **WAYSTAR HOLDING CORP.** |
| By: | /s/ Matthew J. Hawkins | /s/ Matthew J. Hawkins |
|  | Name: | Matthew J. Hawkins |
|  | Title: | Chief Executive Officer |
| By: | /s/ Steven M. Oreskovich | /s/ Steven M. Oreskovich |
|  | Name: | Steven M. Oreskovich |
|  | Title: | Chief Financial Officer |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Matthew J. Hawkins, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Waystar Holding Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.[Omitted];

c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;October 29, 2025 | By: | /s/ Matthew J. Hawkins |
|  |  | Matthew J. Hawkins |
|  |  | Chief Executive Officer |
|  |  | (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Steven M. Oreskovich, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Waystar Holding Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.[Omitted];

c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;October 29, 2025 | By: | /s/ Steven M. Oreskovich |
|  |  | Steven M. Oreskovich |
|  |  | Chief Financial Officer |
|  |  | (Principal Financial Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Waystar Holding Corp. (the "Company") for the quarterly period ended September 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Matthew J. Hawkins, Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;October 29, 2025 | By: | /s/ Matthew J. Hawkins |
|  |  | Matthew J. Hawkins |
|  |  | Chief Executive Officer (Principal Executive Officer) |

---

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Waystar Holding Corp. (the "Company") for the quarterly period ended September 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Steven M. Oreskovich, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;October 29, 2025 | By: | /s/ Steven M. Oreskovich |
|  |  | Steven M. Oreskovich |
|  |  | Chief Financial Officer (Principal Financial Officer) |

---

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

<br>